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ABSTRACT 
 
 
Ex vivo gene transfer can improve the outcome of islet transplantation for treating 
Type I diabetes. Earlier we have shown co-expression of human vascular endothelial 
growth factor (hVEGF) and human interleukin-1 receptor antagonist (hIL-1Ra) after 
transfection of plasmid DNA encoding these two genes. Due to poor transfection 
efficiency of plasmid DNA and the better known islet transduction efficiency of 
adenoviral (Adv) vectors, in this study, we constructed Adv-hVEGF-hIL-1Ra by cloning 
hVEGF and hIL-1Ra coding sequences and polyA signal under separate cytomegalovirus 
(CMV) promoters in Adenoquick plasmid (Ad 13.1). There was dose and time dependent 
expression of these genes after transduction of Adv-hVEGF-hIL1Ra into human islets. 
The mRNA expression of hVEGF and hIL-1Ra was more than 100 times higher than that 
of the non-transduced and bicistronic plasmid transfected control islets. Transduced islets 
were viable as evidenced by insulin release upon glucose challenge. Co-expression of 
hVEGF and hIL-1Ra by islets showed decrease in caspase-3 activity and apoptosis 
induced by a cocktail of inflammatory cytokines such as TNF-α, IL-1β and IFN-γ. 
Compared to non-treated or Adv-LacZ transduced islets, transduction of islets with Adv-
hVEGF-hIL-1Ra prior to transplantation under the kidney capsules of diabetic NOD-
SCID mice reduced the blood glucose levels, and increased serum insulin and c-peptide 
levels. Immunohistochemical staining of the islet bearing kidney sections at day 30 after 
transplantation was positive for human insulin, hVEGF and von Willebrand factor. 
 
Further, we decided to replace VEGF with hepatocyte growth factor (HGF) as it not 
only can promote revascularization of islets but also increases β-cell proliferation. It can 
also protect the islets from apoptosis. Adv-hHGF-hIL-1Ra showed dose and time 
dependent expression of these genes after transduction into human islets and further 
showed significant decrease in caspase-3 induced by the cytokines. Compared to un-
transduced islets, transduction of islets with Adv-hHGF-hIL-1Ra at 1000 MOI prior to 
transplantation under the kidney capsules of streptozotocin-induced-diabetic NOD-SCID 
mice reduced blood glucose levels, and increased serum insulin and c-peptide levels.  
 
These results indicate that the bicistronic Adv vector efficiently expresses both 
growth factor and antiapoptotic genes, decreases apoptosis and improves the outcome of 
islet transplantation. 
 
Liver fibrosis is a consequence of chronic liver disorders which lead to accumulation 
of extra cellular matrix (ECM). Particularly, there is an increased accumulation of 
collagen in the fibrotic liver. We have therefore used a triplex forming oligonucleotide 
(TFO) against the type α 1 (I) collagen and evaluated, whether it can attenuate liver 
fibrosis induced by common bile duct ligation (CBDL). There was a significant decrease 
in hydroxyproline levels in TFO-treated groups compared to non-treated CBDL group. 
Masson’s trichrome staining showed weak staining for collagen in TFO-treated liver 
tissues and there was a predominantly high staining in non-treated CBDL group. There 
was over expression of α-smooth muscle actin (α-SMA), marker for myofibroblasts 
following CBDL. Western blotting analysis also revealed an increase in TGF-β1 
vi 
expression, which is a potential marker for fibrosis in the CBDL group compared to 
TFO-treated group. These results suggest that TFO can be used to downregulate Type I 
collagen gene expression and can alleviate liver fibrosis induced by common bile duct 
ligation. 
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CHAPTER 1. GENE THERAPY AND ISLET TRANSPLANTATION 
 
 
1.1. Introduction 
 
Diabetes mellitus is a chronic metabolic disorder affecting millions of individuals and 
is purported to increase inexorably in the coming decades. It is usually a consequence of 
environmental or genetic factors resulting in elevated blood glucose levels. It is generally 
categorized into two types. Type I or juvenile onset diabetes mellitus is more common in 
children due to failure of islets to secrete insulin. Type II diabetes mellitus is more 
prevalent in adults wherein the amount of insulin produced is not sufficient to control the 
blood glucose levels. It can be a result of insulin resistance or decrease in insulin 
secretion by the beta cells. There is no proper cure for diabetes. Insulin is the only 
treatment for Type I diabetes patients and most existing therapies often fail to provide 
adequate control. There is an urgent need for an effective and better alternative for 
managing diabetes and ultimately a cure. 
 
In Type I diabetes, there is a near depletion of the beta (β)-cell mass, suggesting the 
need for β-cell replacement.1,2 There is also a reduction in the β-cell mass in Type I or II 
diabetes or both. To date, the most effective way of regulating glucose levels is by 
administration of exogenous insulin. However, several studies have shown that insulin 
administration does not decrease the risk of diabetic complications, and hypoglycemia is 
a potential drawback of insulin therapy. This problem is more severe in patients with 
erratic glucose levels or hypoglycemic unawareness. In this scenario, whole organ 
pancreas transplantation seems ideal and it can completely restore the patients to 
euglycemia and maintain long term graft survival. However, the major drawbacks with 
pancreas transplantation are the complications that occur with the major surgery required 
to perform this procedure and the use of immunosuppressants. There are instances where 
simultaneous pancreas kidney transplants have been found beneficial leading to long-
term survival.3 However, pancreas transplantation does not overcome the diabetic 
complications hyperglycemia, hypoglycemia and microvascular and macrovascular 
complications, which are a major concern.4 Also, pancreas transplantation requires major 
surgery and lifelong immunosuppression. 
 
Since the advent of Edmonton protocol in 2000, pancreatic islet transplantation has 
also become a viable alternative for Type I diabetic patients having life threatening 
hypoglycemic episodes. There is a decrease in hypoglycemia and sustained function of 
islets after successful islet transplantation. However, patients becoming insulin 
independent usually lasts for a few years after which they require administration of 
insulin. The major concern with islet transplantation is the use of immunosuppressant’s to 
counteract the immune responses elicited from both the host and the transplanted islets. 
The other major problem is the primary non-function of islets due to hypoxia resulting 
from lack of revascularization or immune mediated destruction of transplanted islets. 
 
In 2000, it was reported that seven consecutive subjects with Type I diabetes were 
rendered insulin free following islet transplantation and according to recent reports 72% 
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of them are insulin independent. The important achievement of this procedure was the 
lack of major surgery for transplanting islets and elimination of hypoglycemia which was 
an important complication in pancreas transplantation or any other therapy for Type I 
diabetes. The other major outcome of this study was that a number of recipients became 
insulin dependent following administration of islets from one donor. However, more than 
50% of the patients who became insulin independent needed insulin within 2 years. There 
was complete graft failure within a few years. This can be attributed largely to continuing 
graft assault by autoimmunity as well as toxicity from immunosuppressive drugs. 
 
Islet transplantation can be done at various sites; however the problems associated 
with transplantation need to be overcome to prolong the survival and metabolic outcome 
of islets. Autologous or auto-transplantation refers to the transplantation of islets isolated 
from the same animal; from same species as allogenic or allo-transplantation and from 
different species as xenogenic or xenotransplantation. 
 
There are several factors that cause the primary non-function of the islet graft. Islet 
primary non-function is the failure of islets to function immediately after transplantation 
due to reasons other than graft failure. During isolation and transplantation islets get 
subjected to different conditions including mechanical stress that may result in non-
function of the β-cells. Several studies have shown that islets fail to function after a 
period of time following transplantation either in the pancreatic cavity or in the peritoneal 
cavity.5,6 There was a significant depletion of islet mass indicating that primary non-
function is one of the major reasons we need a large number of islets to achieve 
euglycemia. Efficient isolation of pure islets, without altering their physical appearance is 
vital for successful transplantation. Islets are the endocrine part of the pancreas and they 
need to be separated from the exocrine cells while keeping the intra-islet association 
intact. The enzyme collagenase is used to disrupt the islet cells interaction with exocrine 
cells followed by separation using density gradient centrifugation. The whole process has 
been optimized and pure, viable islets are being successfully isolated. 
 
Islets have extensive intra-islet vasculature which gets disrupted during their 
isolation. This vasculature is essential for the supply of nutrients and oxygen to the islets. 
Since this vasculature gets disrupted during isolation, revascularization is very essential 
for the viability and function of islets following transplantation. Islets get revascularized 
by secreting pro-angiogenesis molecular mediators like vascular endothelial growth 
factor (VEGF) and its receptors. Therefore, ex-vivo gene delivery of VEGF to islets or by 
co-encapsulating VEGF protein with islets can promote revascularization in islets. 
 
Type I diabetes is an autoimmune disorder which poses several challenges for islet 
transplantation. Diabetes shows the presence of β-cell reactive auto antibodies and T-
cells. The specific nature of T-cells is not known and these can elicit an autoimmune 
reaction following transplantation resulting in the destruction of β-cells. The host also has 
preexisting antibodies and primed immune cells against β-cell surface epitopes and 
immune cells that infiltrate in response to non-self antigens resulting in graft destruction. 
Apart from this, the host also reacts to non-self proteins from the transplant tissue 
resulting in the loss of islet function. 
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Usually when a foreign tissue is introduced into the host by transplantation, foreign 
antigens are recognized by the host leading to a cascade of events called antigen 
presentation. The various peptide fragments, secreted and shed proteins come in contact 
with the host immune cells forming a major histocompatibility complex (MHC).7 MHC 
can be either class I or II and usually autoimmunity occurs when there is matching for 
MHC class II.8 Class II molecules are only expressed in certain immune cells including 
macrophages and dendritic cells known as antigen presenting cells (APCs). APCs can be 
either from the host or from the donor. The antigens present on MHC II molecules on the 
donor APCs acts as foreign antigens to the transplant recipient when the lymphocytes 
migrate in the host. Donor antigen presentation can be mediated either through direct or 
indirect pathways. Direct pathway engages antigen presentation by the donor APCs, 
while the indirect pathway engages host APCs. Understanding the pathways involved in 
immune destruction of transplanted islets is critical for developing strategies to protect 
them. 
 
Various immune suppressive strategies are employed to minimize or block the 
immune activation. Immunosuppressive drugs are often employed with transplantation. 
However, the risks from these drugs are unknown and they may further inhibit the graft 
function. Therefore, there is a need for improvements in immunosupprresion and also 
improvement in the quality of islets. 
 
The potential use of genes as therapeutics has attracted great attention for the 
treatment of severe and debilitating diseases. Gene therapy is the method of treating 
diseases using genes so that the patient’s somatic cells can produce the specific proteins 
that are lacking. This will prevent the limitations associated with the administration of 
therapeutic proteins. It is an approach to treat diseases, or ultimately prevent a disease by 
replacing defective genes, introducing new genes, or changing endogenous expression of 
genes. Gene therapy can be used to express genes that can aid in the process of islet 
transplantation and improve the overall survival and function of islets. It can aid in 
modifying the islets resulting in improved survival and function of islets post-
transplantation. Current gene therapy approaches are mainly oriented to improve islet 
function, block apoptosis and inhibit primary non-function of islets. The various gene 
vectors that are being used for islet transplantation include adenoviral, adeno-associated 
virus, herplex simplex virus vectors, retro and lentiviral vectors and non-viral vectors. 
The main problem associated with viral vectors is immunogenicity and safety concerns. 
Anti-apoptotic, angiogenic genes are most commonly expressed using these vectors to 
improve the metabolic function and survival of islets following transplantation. 
 
Gene therapy uses viral or non-viral vectors to deliver genes to synthesize specific 
therapeutic proteins. Viral vectors are derived from retroviruses, lentiviruses, 
adenoviruses, adeno-associated viruses, herpes viruses and pox viruses.9 The 
development of vectors for cell-specific gene expression is the major goal of any gene 
therapeutic strategies. Significant progress has been made in the construction of gene 
expression vectors that combine different functions required for efficient gene transfer.10  
 
Gene medicine usually contains an expression system that controls the transcription  
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of a gene within the target cell and a specific delivery system that controls the 
biodistribution of these vectors to specific locations in the body. Cationic liposomes, 
peptides and polymers are commonly used as transfection reagents for gene expression 
plasmids, while viral vectors usually do not require any of these transfection reagents. 
 
Viral vectors have shown much promise in the field of gene therapy, but there are 
safety issues, they may also be limited in terms of their DNA loading capacities.10 
Immune activation by viral vectors is a major concern as many of the vectors with high 
therapeutic activity in vitro fail to do so in vivo.11 Moreover, increasing their yield can be 
quite difficult. To minimize their immunogenicity, the surface of the viral vectors is often 
modified by conjugating to polyethylene glycol (PEG).12 
 
Gene expression plasmids offer many advantages over viral vectors, including large 
packaging capacity, no integration into the host genome, and lower toxicity. However, 
their level of gene expression is often lower and shorter than that of the viral vectors. 
Recent advances in gene expression systems have shown great improvement in the 
transfection levels of non-viral vectors. Plasmid vectors can also be used to silence a 
gene, thereby causing the inhibition of an abnormal protein production in the body.13 
Plasmids have also shown to play a role in the formation of viral vectors, e.g., two 
plasmid rescue systems used to construct an adenoviral vector. The various parts of the 
gene expression system are outlined here. 
 
 
1.2. Gene Expression Systems 
 
Gene expression systems are broadly classified into plasmid and viral vectors. 
Basically, these vectors have the machinery in them to facilitate the production of target 
proteins in the host upon transfection or transduction. 
 
 
1.2.1. Basic Components of Plasmid Vectors 
 
A gene expression plasmid contains a complementary DNA (cDNA) sequence coding 
for either a full gene or minigene, and several other genetic elements including promoter, 
introns, polyadenylation (polyA) sequences, and transcript stabilizers to control the 
transcription, translation, and protein stability and/or secretion from the host cell.14 
 
The transcription unit comprises of 5’ enhancer/promoter upstream of the gene 
encoding a therapeutic protein and polyA signal downstream of the gene. An intron is 
also assembled into either 5’ or 3’ untranslated region (UTR), leading to elevation of 
mRNA levels. Plasmid vectors can be designed to express two genes simultaneously 
driven by different promoters or a single promoter or by insertion of an internal ribosome 
entry site (IRES). IRES was first discovered in picornaviruses, Encephalomyocarditis 
Virus (ECMV) and poliovirus.15,16 They have the ability to translate two open reading 
frames from a single mRNA transcript. Usually the IRES is inserted between two 
transgenes to be expressed. IRES confers unequal expression of genes and usually the 
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expression of the downstream gene is relatively higher than the upstream gene and this 
may confirm the internal ribosome entry.16 However, recent studies have shown that this 
may not be always true. Production of low level of monocistronic RNAs putatively due to 
splicing of the bicistronic transcript due to the presence of 3’ splice site (SS) which can 
show increased expression of the downstream gene.17 This warrants a careful RNA 
structural analysis to confirm the functionality of the IRES. 
 
We have constructed a bicistronic plasmid vector (phVEGF-hIL-1Ra) encoding 
human vascular endothelial growth factor (hVEGF) and human interleukin-1 receptor 
antagonist (hIL-1Ra) driven by cytomegalovirus (CMV) and elongation factor-1α (EF-
1α) promoters, respectively, in pBudCE4.1 vector.18 There was dose and time dependent 
expression of hVEGF and hIL-1Ra genes when they were transfected into human islets. 
However, the expression levels of these two genes were not sufficient to decrease blood 
glucose levels of diabetic mice following transplantation with phVEGF-hIL-1Ra 
transfected islets. Not only the expression, but the extent of expression of genes was also 
low for this bicistronic plasmid. 
 
1.2.1.1. Bacterial Elements 
 
Plasmids encode two features that are important for their propagation in bacteria. One 
is the bacterial origin of replication (Ori), which is a specific DNA sequence that binds to 
factors that regulate replication of plasmid and in turn control the number of copies of 
plasmid per bacterium. The second required element is a selectable marker, usually a 
gene that confers resistance to an antibiotic. The marker helps in the selection of bacteria 
that have the gene expression plasmid of interest. Escherichia coli (E.coli) are commonly 
used bacteria for propagating plasmids. It has the property to transfer DNA either by 
bacterial conjugation, transduction or transformation. The extensive knowledge about 
E.coli’s physiology and genetics accounts for its preferential use as a host for gene 
expression. Human insulin was the first product to be produced using recombinant DNA 
technology from E.coli. 
 
1.2.1.2. Transcription Regulatory Elements (TRE) 
 
Gene expressing plasmids contain transcription regulatory elements (TRE) to control 
transcription. The Jacob and Monad theory postulates that a repressor protein may bind to 
the operator region downstream of a promoter preventing RNA polymerase from binding 
to the host DNA.19 This operator region may overlap with the promoter for the operon 
being controlled. However, if this repressor is controlled, it may increase gene 
expression.20 Transcription regulatory elements play a significant role in gene expression 
and may also impart specificity. The important sequences in the gene that control 
transcription are the cis-acting sequences that are situated in the immediate vicinity of the 
gene and they together constitute the functional unit or domain.21 
 
Heterologous TREs can be included in the adenoviral genome to allow replication 
only in the cells in which TREs are functional, resulting in cell specificity.22 Addition of 
new TREs in an expression vector can alter the transcription of the target gene. These 
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new elements can mimic the action of the genomic TREs of the target genes resulting in 
an alteration in transcription. These elements can be added to either increase or decrease 
transcription depending on the requirement. In diseases like cancer, the expression of 
target genes can be altered by this method.23 For example, homeodomain-containing 
transcription factor pancreatic duodenal homeobox-1 (Pdx-1) plays a key role in 
maintaining the function of pancreas and is also known to have a prominent role in beta 
cell development.24 When this Pdx-1 was introduced into an adenoviral vector and 
expressed in hepatocytes, they were transformed into pancreatic endocrine hormone 
producing cells.25 Modulating the expression vector with TREs can be done to increase 
the gene expression. Embryonic stem cells have the potential to transform into insulin–
producing cells that can be transplanted for treating Type I diabetes.26 TREs can play a 
major role in transformation of these cells. 
 
1.2.1.3. Enhancer  
 
Enhancer is a short region of DNA that can bind trans-acting factors, much like a set 
of transcription factors, to enhance transcription levels of genes in a gene-cluster. Usually 
in the bound proteins facilitate promoter-binding proteins to interact with the promoter.27 
An enhancer does not need to be particularly close to the genes it acts on, and need not be 
located on the same chromosome. An enhancer does not need to bind close to the 
transcription initiation site to affect its transcription, as some have been found to bind 
several hundred thousand base pairs upstream or downstream of the start site.28 
Enhancers can also be found within introns. An enhancer's orientation may even be 
reversed without affecting its function. Furthermore, an enhancer may be excised and 
inserted elsewhere in the chromosome, and still affect gene transcription.29 That is the 
reason why intron polymorphisms are important, even though they are not transcribed 
and translated. Enhancer-promoter interaction also plays a major role in immune reaction 
following in vivo administration of plasmid vectors. Epo enhancer when inserted into the 
plasmid expressing VEGF showed expression of VEGF in hypoxia conditions, whereas 
the plasmid without epo enhancer showed no expression of VEGF.30 
 
1.2.1.4. Promoter  
 
Promoter is a DNA sequence that enables a gene to be transcribed. The promoter is 
recognized by RNA polymerase, which binds it and then initiates transcription. 
Promoters regulate protein synthesis indirectly by having an active role in demarcating 
genes to be used for mRNA synthesis. The promoter region is usually the beginning of an 
operon, which is a collection of neighboring genes, and controls the region transcribed 
into the same mRNA molecule.31 Therefore, DNA transcription begins after RNA 
polymerase has bound downstream of the therapeutic gene. This effect is seen as DNA 
unwinding into single strands. Therefore, any mutation in this region will prevent RNA 
polymerase from binding. Transcription begins at the first base of the target gene+1 
position is the TATAA sequence or TATA box, 5’ TATA (A/T) A (A/T)-3’. This region 
ensures that transcription starts at the proper point and binds the RNA polymerase II  
complex.32 Another transcription start site is the CCAAT box (consensus sequences 5’-
GGTC-CAATCT-3’) located upstream of the TATA box. 
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Promoter sequences play an important role not only in initializing gene transcription, 
but also in immunostimulation.33 The promoter type governs the strength and duration of 
transgene expression. Viral promoter elements are first known to be used in an expression 
vector to express proteins for gene therapy. Cytomegalovirus (CMV), Rous sarcoma 
virus (RSV) and Simian virus 40 (SV40) are some of the strongest known viral 
promoters. However, there are some drawbacks with the use of viral promoters such as, 
lack of specificity and immunostimulation that results in inactivation. For example, CMV 
promoter shows expression in most cell types, however, its activity decreases over a 
period of 3-4 weeks.34 This is possibly due to the inhibition by cytokines, methylation, or 
inactivation by repressor proteins. This is also true for other viral promoters like SV 40 
and RSV.35 Because of these reasons there is an urgent need to develop promoters based 
on non-viral cellular regulatory elements.  
 
Sustained gene expression is quite difficult to achieve. However, some promoters 
have been reported to confer sustained gene expression from plasmid DNA in vivo. These 
promoters include β-actin, elongation factor 1-α, (EF1-α), or ubiquitin. The activity of 
these promoters is usually lower than that of viral promoters, but can be increased by 
addition of viral or cellular enhancer components.36 CMV early enhancer/chicken β actin 
(CAG) is a promoter of this kind. It consists of CMV enhancer and first intron of chicken 
(or human skeletal) β-actin. It shows activity similar to or more than the CMV 
promoter.37,38 It shows a greater activity in viral vectors, but its expression profile needs 
to be established for using in plasmid vectors.35  
 
EF1-α promoter has been reported to confer sustained gene expression compared to 
CMV promoter, but its expression is 10-fold lower than the CMV promoter.39 Promoters 
from three of the known human ubiquitin genes, UBA, UBC, UBB have been 
incorporated in plasmid vectors. Luciferase gene expression was measurable upto 6 
months when the plasmid contained UBC promoter.39 This clearly suggests that if proper 
promoters are incorporated into the gene expression system, it is possible to attain 
sustained gene expression. Primary bone marrow-derived mesenchymal stromal cells 
(BMMSC) were inserted with glucose-responsive promoter-regulated insulin transgene. 
HBMMSC glucose-responsive promoter, EGR1 was identified from these cells which 
showed rapid glucose-induced transgene secretions simulating normal human islets.40 
 
1.2.1.5. Untranslated Region (UTR) 
 
The 5’ untranslated region (5’-UTR) is the region of the mRNA transcript that is 
located between the capsite and the initiation codon. The linkage between methylated G 
residue and 5’ to 5’ triphosphate bridge is known as the cap structure, which is essential 
for efficient initiation of protein synthesis. The 5’-UTR is known to influence mRNA 
translation efficiency. In eukaryotic cells, initiation factors first interact with the 5’ cap 
structure and prepare the mRNA by unwinding its secondary structure. An efficient 5’-
UTR is usually moderate in length, devoid of secondary structure and upstream initiation 
codons. It has AUG with an optimal context. Any of the following features that influence 
the accessibility of the 5’ cap structure to initiation factors will influence mRNA 
translatability.41,42 
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Initiation codon AUG appears to be the best recognized when it is in the context of 
the sequence CCRCCAUGG with purine (R) at -3 and/or guanine (G) at+4 (A of AUG is 
numbered+1). If an AUG occurs alone or in conjunction with a short open reading frame 
located between the cap site and the genuine AUG, translation will be inhibited. 
Secondary structures of the UTRs inhibit translation. 5’ UTR lengths that are greater than 
32, but less than 100 nucleotides, permit efficient recognition of the first AUG. Most 
naturally occurring 5’ UTRs are 50-100 nucleotides in length. 
 
The 3’ UTR comprises the mRNA sequence following the termination codon. It plays 
an important role in mRNA stability.31 AU rich motifs are commonly found in the 3’ 
UTR of mRNA of cytokines, growth factors, and oncogenes. These are mRNA instability 
elements and should be removed for maximal gene expression. This is achieved when 
standard 3’ UTR sequence is used in the place of one found in cDNA. Another way is to 
minimize the length of the 3’ UTR by placing the hexanucleotide of the poly A signal 
immediately downstream of the stop codon.43 
 
1.2.1.6. Polyadenylation (polyA) Signal 
 
The efficiency of polyadenylation (polyA) is important for gene expression, as 
transcripts that failed to be cleaved and polyadenylated are rapidly degraded in the 
nuclear compartment.44 PolyA signal is a recognition site consisting of AAUAAA 
hexamer positioned 10-30 nucleotides upstream of the 5’ end and a GU or U rich element 
located maximally 30 nucleotides downstream of the 3’ end.31 PolyA signal is needed for 
the formation of the 3’ end of most eukaryotic mRNA. It directs two RNA processing 
reactions: site specific endonucleolytic cleavage of the RNA transcript, and stepwise 
addition of adenylates to newly generated 3’ end to form the polyA tail.  
 
1.2.1.7. Intron 
 
The protein coding region in the gene is often interrupted by stretches of noncoding 
DNA called intron. Transcripts from intronless genes are rapidly degraded in the nuclear 
compartment, leading to lower gene expression.45 Therefore, for maximal gene 
expression in eukaryotic cells, at least one intron should be included within the 
transcription unit. Introns also promote mRNA export from the nucleus. The addition of 
intron A or B to the plasmid encoding ICAM-2 promoter and subsequent expression in 
HUVEC or PsCAM cells increased the expression of the transgene.37 Introns thus can 
affect gene expression and if used in a proper way can enhance the expression of 
transgenes. 
 
1.2.1.8. Stop Signal 
 
Stop signal is the DNA sequence at which RNA polymerase II is halted and detached 
from the DNA, thereby a stop or nonsense codon stops translation. However, polyA 
occurs at 5’ AAUAAA 3’ sequence in the mRNA. The polyA polymerase cleaves after 
the U residue and adds 50-250 adenylate residues. Stop signal not only plays an 
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important role in gene regulation at the translational level allowing for rapid changes in 
specific protein levels, but also provides an opportunity to alter codon specificity. 
 
1.2.1.9. Multiple Cloning Sites (MCS)  
 
A multiple cloning site (MCS), also known as polylinker, is a short segment of DNA, 
which contains many restriction sites. Restriction sites within an MCS are unique and 
occur only once within a particular plasmid. MCS are commonly used for cloning of a 
single or multiple cDNAs due to its unique restriction endonuclease recognition sites 
identified with ease. The recombinant plasmid can be altered in such a way that the 
desired gene can be inserted into the plasmid and expressed. If there is no particular 
restriction site for a particular transgene, the restriction site can also be inserted into the 
MCS and then can be used to clone the gene in that vector. 
 
1.2.1.10.   Fusion Tags  
 
Fusion tags are inserted in expression systems so that the DNA location and site 
specificity can be known. A variety of protein tags have been used to allow recombinant 
fusion protein to be detected and purified without the use of an antibody or other protein 
specific assays. Short epitope tags and fluorescent protein tags are commonly used for 
gene function studies. Epitope tags such as His/C-term, xpress, V5, FLAG, HA, and c-
Myc, circumvent the requirement for specific antibodies against target proteins. 
Fluorescent protein tags, such as green fluorescent protein (GFP) provides information on 
the cellular location of the fusion proteins. Since addition of the any amino acid residues 
may alter the properties of the target proteins, special consideration should be given on 
the intended use of the protein and on minimizing the adverse effects when picking a tag. 
Typically, a specific protease cleavage site is introduced in the tag and the target protein 
to facilitate tag removal if desired. Fusion tags can be incorporated into the plasmid 
vectors to enhance protein expression and solubility of the expressed protein.46 Fusion 
tags can be classified into two types based on their application: Affinity tags and 
solubility enhancing tags. Affinity tags help in purification of recombinant protein, 
whereas the solubility-enhancing tags can be used to improve the solubility of proteins. 
Usually the solubility enhancing tags are either large peptides or proteins. Fusion tags 
like glutathione S-transferase (GST) and maltose binding protein (MBP) show both 
affinity and solubility enhancing properties.47,48 Recombinant proteins often show large 
variability in their expression, solubility, stability, and function, making them difficult 
targets for large-scale analyses and production. Fusion tags can be very effective in 
improving the expression, solubility, and production of biologically active proteins, 
especially for proteins whose expression is very difficult. 
 
 
1.2.2. Persistence of Gene Expression 
 
Regulation of gene expression and having a sustained expression is the key for many 
diseases. Plasmid based systems usually confer transient gene expression, with less than 
20% of the peak level at day 3.49 This warrants the need for expression of transgene over 
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a period of time. This is especially important in diseases like cancer where the cells 
divide continuously. An ideal non-viral vector should be able to provide persistent 
expression of the transgenes without affecting the host cells. Persistent gene expression 
can be achieved either by prevention of promoter attenuation, use of replicating plasmid, 
modulation of immune response, attachment of matrix/scaffold regions or optimizing 
plasmid size. 
 
1.2.2.1. Prevention of Promoter Attenuation  
 
The major drawback of non-viral vectors is the lack of sustained gene expression. 
Transient gene expression in vivo is partly due to promoter shutdown.35 This is especially 
true for viral promoters, such as CMV and SV 40 promoters. Methylation of plasmid 
DNA is involved in promoter inactivation, which can be prevented by removing the 
methylation sites (CpG motifs) from the plasmid construct. Transient gene expression is 
also due to the destruction of the transfected cells by the immune system.50 Viral 
promoters are sensitive to cytokines, which may explain the decline of their activity in 
vivo.35 Promoter inactivation has also been attributed to specific tissue types. For 
examples, smooth muscle gamma actin (SMGA) and flk-1 promoters show their activity 
specifically in smooth muscles and endothelium, respectively.10 
 
1.2.2.2. Use of Replicating Plasmids  
 
Extrachromosomally replicating vectors have great potential for use in gene therapy 
due to their high transfection levels and sustained expression of transgenes. The use of 
replicating plasmids results in sustained gene expression without the integration of gene 
into the host genome. This also reduces the risk of insertational mutagenesis. Replication 
elements usually from viral DNA are inserted into the expression systems that enable the 
plasmid to replicate extra chromosomally. This can be done by the introduction of a 
mammalian origin of replication51 sequence into plasmid. The best characterized oris in 
mammalian cells are from viral sources, such as SV40, human papo virus (BKV), bovine 
papilloma virus (BPV), and the Epstein Barr virus (EBV).52 Modeling the bacterial power 
and efficiency of self-replication would greatly increase therapeutic protein expression.  
 
Since the plasmids do not integrate into the host genome, they reside outside as 
episomes. They have several advantages over integrating systems: (1) the transgene is not 
interrupted or subjected to regulatory constraints that often occur from integration into 
cellular DNA, (2) higher transfection efficiency, (3) episomes show a low mutation rate 
and tend not to rearrange, and (4) they have the ability to transfer large amounts of 
DNA.10 
 
Plasmids can replicate in both prokaryotic and eukaryotic cells provided they have 
certain elements which allow them to do that, e.g., EBV viral elements.53,54 Several viral 
constructs including EBV, BK virus (BKV), SV 40 and bovine papilloma virus have been 
used in constructing replicating plasmid vectors. Trans-acting factors are needed for the 
formation of episomal vectors, but there is a risk of transformation following their use. 
This is especially seen in the case of polyomaviruses (BKV, SV40) which contains a T-
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antigen (Tag) as a trans-acting factor. Tag purportedly binds to tumor suppressor gene 
p53 causing chromosmal aberrations and alters the gene expression.55 Considering this, 
EBV viral elements are safer as they have a low mutation frequency and can easily 
incorporate large amounts of DNA.55 EBV nuclear antigen 1 (EBNA1) and oriP 
constitute the EBV viral elements which impart stability to the viral DNA in the host 
cells.53,55 EBNA1 dimer/oriP complex controls the replication and transcription of 
plasmid vector. EBNA facilitates binding of the plasmid vector to the nuclear matrix. 
EBV–based vectors showed higher expression of transgenes compared to conventional 
vectors when they were studied in vivo. However, EBV based vectors are associated with 
certain drawbacks including integration into the host genome and oncogenicity.55 
Ehrhardt et al., replaced the CMV promoter with a cellular promoter to minimize the 
silencing effects attributed to nonmammalian sequences.56 However, if the problems 
associated with the use of viral elements can be solved, they can be far superior compared 
to the conventional vectors. 
 
1.2.2.3. Modulation of Immune Response 
 
One of the major drawbacks of gene therapy is the interaction of the gene expression 
vectors with the host immune system. Although non-viral vectors produce less immune 
response compared to viral vectors, their effect should not be overlooked. CpG motifs are 
unmethylated with an ability to stimulate B cell proliferation, macrophage activation and 
maturation of dendritic cells. The bacterial and viral DNA contains a large amount of 
unmethylated CpG motifs. Plasmid vectors usually contain bacterial or viral elements 
with large number of CpG motifs, which lead to acute inflammatory response commonly 
seen in non-viral vectors. The sequence GTCGTT is the most active stimulatory CpG 
motif in humans leading to the activation of immune pathways. Following activation of 
the immune system by CpG motifs, gene expression is decreased due to cytokine 
mediated promoter shutdown and apoptosis of expressing cells. 
  
When constructing plasmid vectors the immunostimulation of the CpG motifs can be 
reduced by methylation of the CpG motifs, using neutralizing CpG motifs or by 
elimination of CpG motifs. Plasmid vectors containing significantly less amount of CpG 
motifs showed very less immunostimulation compared to the ones with more CpG 
motifs.57 The presence of a single unmethylated CpG has been shown to elicit an 
inflammatory response when delivered to lung. However, CpG free vectors showed no 
inflammatory response and increased the duration of transgene expression in the lung.39 
Li et al., have shown that intradermal injection of plasmid DNA encoding glutamic acid 
decarboxylase (GAD) polypeptide synthesized in both pancreatic islet and skin tissue and 
pro-apoptotic protein BAX, ameliorated new-onset Type I diabetes in NOD mice and 
increased skin allograft survival in a BALB/c-C57BL/6 model system in a donor-specific 
manner by preventing the autoimmune response that elicited following skin 
transplantation.58 Plasmid gene expression has resulted in expression of T-cells 
previously, whose effect can be negated by administering the plasmid DNA encoding this 
peptide.  
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1.2.2.4. Matrix/Scaffold Attachment Regions (MARs) 
 
Matrix/scaffold attachment regions (MARs) govern the architecture of the nucleus by 
establishing protein boundaries. Several proteins bind to MARs and these proteins are 
known as MAR binding proteins. MAR binding proteins are very significant as they 
regulate transcription, replication, repair and combination.59 Incorporation of matrix 
attachment regions in the plasmid construct may be thus helpful in maintaining episomal 
plasmid for extended periods. The potentially immunostimulatory and transforming 
properties of viral protein used in episomes and other components of the expression 
system impede the application of these systems for gene therapy. Alternatively MARS 
can be incorporated into circular plasmids to replace transacting viral gene products. 
MARs have been characterized as AT rich sequences generally composed of 4-6 bp 
motifs such as ATTA, ATTTA, or ATTTTA.60 These sequences are commonly used with 
gene enhancers and the ori. Incorporation of these sequences has been used to enhance 
the transcriptional activity of integrated transgenes.60  
 
MARs are often situated in proximity to promoters, replication origins and other 
important regions in the genome. MARs have been known to play a role in several 
biological activities due to their affinity to the nuclear matrix. They have been known to 
play a role in initiation of transcription, promote long term expression of the transcript by 
counteracting the effects of DNA methylation, protect transgenes from negative effects of 
the genomic surroundings and promote histone acetylation, act as an enhancer and 
promote replication.61 MARs have been incorporated in episomally replicating plasmids 
to impart stability to the vector and increase the longevity of transgene expression. MARs 
are used to replace the viral elements from these vectors to minimize the 
immunostimulatory effects from them. An episomal vector was developed by replacing 
the Tag protein with MAR from human β-interferon gene while retaining the SV40 ori 
sequence. This vector replicated episomally in CHO cells and showed stable expression 
for more than 100 divisions. Argyros et al.,62 demonstrated persistent transgene 
expression in the liver after hydrodynamic injection of the plasmid containing MARs 
driven by human liver specific promoter α1-anti-trypsin (AAT). MARs protected the 
AAT promoter by inhibiting methylation of CpG motifs, resulting in sustained expression 
of luciferase,62 while the plasmid containing MARs and CMV promoter did not show 
persistent luciferase expression. This signifies that even though MARs imparts extra-
chromosomal stability, duration of gene expression also depends on the choice of 
promoter used. 
 
1.2.2.5. Plasmid Size 
 
Plasmid stability is dependent on its size. Most gene therapy studies use plasmids of 
less than 10kb. To prolong gene expression, bacterial artificial chromosomes (BAC) have 
been used in non-dividing cultures.63 A BAC-plasmid vector encoding 185kb DNA insert 
of human beta globin gene and EBV orip and EBNA-1 transactivator showed persistent 
gene expression indicating the usefulness of plasmid size.64 A episomal BAC vector 
encoding entire genomic human low-density lipoprotein receptor (LDLR) and LacZ 
showed high transfection and persistent gene expression of LDLR and LacZ.65 
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Bacterial components in the plasmid vector are known to elicit immunostimulation. 
Therefore, several research groups are investigating the possible use of minicircle 
plasmids, which do not have bacterial origin of replication or antibiotic resistance marker. 
These are generated in E.coli by site-specific recombination. Following injection of 
minicircle plasmid encoding VEGF165 into Balb/c mouse heart and skeletal muscle, 
VEGF165 gene expression levels were similar or higher to that observed with 
conventional plasmid vectors encoding VEGF165.66 In another study, minicircle mediated 
delivery of interferon-γ (IFN-γ) was more efficient in inducing antiproliferative and anti-
tumor effects in human nasopharyngeal cancer cell lines than conventional vectors due to 
its sustained expression of IFN-γ levels.67 This suggests that minicircle plasmids may be 
a viable alternative to conventional plasmids vectors. 
 
 
1.2.3. Site-Specific Gene Expression 
 
Targeting of gene medicines to specific cells is often required to prevent toxicity to 
healthy cells and to decrease the required dose. Differential gene expression among cell 
types is possible because different genes are driven by different sets of promoters and 
enhancer sequences, and each of these regulatory binding sequences contain binding sites 
for multiple transcription factors. Changing the set of transcription factors will lead to the 
activation of a different set of genes, leading to a change in the cell’s protein expression 
profile. Selective expression of transgenes in specific cells or tissues can be achieved by 
constructing DNA expression cassettes that contain gene regulatory regions that are 
recognized by transcription factors, specially present in or selectively expressed by the 
target cell population. This targeting is based on tissue specificity where transcription is 
directed specifically among healthy tissues or tumor specific by using elements which are 
active in tumor cells due to aberrant gene expression or tumor biology. 
  
There are various well characterized regulatory elements controlling cell type specific 
expression, with target tissues including pancreas, breasts, bone, brain, kidney, bladder, 
lung, and liver. Tissue specific promoters display a natural activity in normal tissues 
without discriminating diseased cells from healthy ones. Therefore, for toxic protein 
expression the use of tissue specific promoters is limited to dispensable tissues such as 
melanocytes, prostate, breasts, endocrine, and exocrine tissues.12,68,69 Combining tissue 
specific promoters with additional targeting moieties can further increase their utility. For 
example, combination of tumor and tissue specific promoters may enable targeting 
specific cells/malignancies within nondispensable tissues. Cellular regulatory elements 
often have low activity, which can be addressed by inclusion of a strong promoter 
element from viral or cellular origin. For example, Pujal and colleagues have shown the 
specificity of the keratin 7 promoter which is expressed in pancreatic ductal cells 
predominantly than acinar cells which depends on the krt 7-234 bp sequence. This 
sequence is included in a plasmid or viral vector exhibits the same specificity as krt7 
promoter and may help in targeting pancreatic ductal adenocarcinoma cells in vitro and in 
vivo.70 Targeting expression to a particular organ, tissue and cells greatly reduces the 
antibody response to a foreign protein and results in sustained expression.71 
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Most composite promoters contain one or two enhancer elements fused to a 
heterologous promoter sequence. This concept has been used to create promoters with 
combinations of regulatory sequences. Li et al., randomly assembled muscle-specific 
elements from four different muscle-specific promoters and then screened these novel 
promoters for activity.72 One sequence showed 8-times the activity of natural muscle 
promoters. However, this was done in vitro. It is more challenging to develop a promoter 
with greater expression in vivo. 
 
 
1.2.4. Pulsatile Gene Expression 
 
Gene switches are introduced into expression systems to make use of circadian 
rhythm by extraneously administering compounds to control the production of 
therapeutic proteins by turning on or off the transcription of an administered gene. Gene 
switches are incorporated into the vector for gene regulation. This feedback control may 
prevent overexpression and possible deleterious protein production. In this system the 
target gene is inactive until the administration of an exogenous compound or ligand.73,74 
Progesterone antagonists, tetracycline, ecdysone and rapamycin are used as inducing 
agents to turn on gene regulation of the expression vector. 
 
 
1.3. Viral Vectors 
 
Recombinant viruses are unique in being naturally evolved vehicles that efficiently 
transfer their genes into host cells. Viral vectors are composed of either a RNA or DNA 
core, or process different genomic structure and host ranges. However, they often have 
risks such as toxicity, immunogenicity, and/or potential for viral recombination. Novel 
developments of viral vectors mainly aim at reduction of immunogenicity and improved 
vector production. Several kinds of viruses including retrovirus, adenovirus (Adv), 
adeno-associated virus (AAV), herpes simplex virus (HSV), have been manipulated for 
gene transfer and are commonly used for modifying islet cells to improve their survival 
and enhance their metabolic activity. These viral vectors have their own unique 
advantages and disadvantages as discussed below. 
 
 
1.3.1.  Retroviral Vectors  
 
Retroviruses are enveloped single stranded RNA viruses. Retroviruses have a genome 
of about 7-10kb, composed of gag, pol, and env genes flanked by elements called long 
terminal repeats (LTRs). These are essential for integration into the host genome and 
signify the beginning and end of the viral genome. The LTRs control the expression of 
viral genes, and hence act as enhancer- promoter. The final element of the genome, the 
packaging signal (ψ), helps in differentiating the viral RNA from the host RNA.75 Gag 
proteins are major components of the viral capsid. Pol proteins are involved in the 
synthesis of viral DNA and integration into the host DNA, whereas env proteins play a 
role in association and entry of viral particles into the host cell. 
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The viral genome can be manipulated and viral genes can be replaced by inserting 
transgenes. The transgenes can be controlled by the LTRs or alternate enhancer-promoter 
sequences can be engineered within the transgene. The chimeric genome is then 
introduced into packaging cell lines, which produce all the viral genes but these have 
been separated from the LTRs and the packaging sequence. So, the chimeric viral 
genomes are assembled to produce the retroviral vector. The culture medium containing 
the packaging cells which produce the retroviral vector is used directly to infect target 
cells for gene transfer. 
  
Retroviral vectors have several advantages including stable transduction of dividing 
cells, less immunogenic and persistent transgene expression. However, there are several 
disadvantages of these vectors. These include random insertion into the host genome, 
limited DNA insertion capacity (8kb), low titers, and inactivation by complement 
systems, and inability to transduce non-dividing cells. 
 
LIM-homeobox transcription factor islet-1 (Lsl1) is a transcription factor derived 
from heart during embryogenesis that has the ability to self-replicate was delivered to the 
endothelial cells and mesenchymal stem cells (MSCs) using a retroviral vector resulting 
in promotion of angiogenic and vasculogenic properties. Lsl1 expressing endothelial cells 
also promoted vascularization in vivo in C57BL/6J mice.76 
 
 
1.3.2. Lentiviral Vectors  
 
Although lentiviral vectors belong to the retroviral family, they have the ability to 
infect both dividing and non-dividing cells.77 Human immunodeficiency virus (HIV) is 
the best known lentivirus.78 HIV lentiviral vector is very efficient as it has the ability to 
infect and express genes in human helper T cells and macrophages. Apart from the genes 
gag, pol and env, the HIV has six accessory proteins tat, rev, vpr, vpu, nef, and vif. These 
proteins regulate the synthesis and processing of viral RNA and other replicative 
functions. The accessory proteins can also be removed without affecting the production 
efficiency of the virus. The env gene from HIV-based vectors allows the infection of cells 
which express protein CD4+, so in these vectors this is substituted with other env gene 
from other RNA viruses which have a broader infection spectrum. 
 
The significance of lentiviral vectors lies in the fact that they can efficiently transduce 
non-dividing cells or terminally differentiated cells such as neurons, macrophages, 
hematopoietic stem cells, muscle and liver cells and other cell types for which gene 
therapy methods could not be used. These vectors, when injected into the rodent brain, 
liver, muscle, or pancreatic islet cells, show a sustained gene expression for over six 
months.79 These vectors do not show any immune response and no potent antibody 
response and thus can be ideal for in vivo gene delivery. 
 
Magnetic nanoparticles have been used for the delivery of lentiviral vectors to 
endothelial cells. This method provides the direct targeting of the lentiviral vectors to 
endothelial cells even in perfused blood vessels apart from increasing the transduction 
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efficiency.80 However, one problem with lentiviral vector is random integration into 
genomic DNA. This integration although desirable can be problematic as it can cause 
differential gene expression in the cells and most importantly insertational mutagenesis 
resulting in malignant transformation. To alleviate this effect non-integrating lentiviral 
vectors are developed by point mutations into the chromosome binding site, the viral 
DNA binding site of the viral integrase.81 
 
There are reports in the literature where they have used lentiviral vectors encoding 
immunosuppressive proteins to protect the islets from allogenic rejection.82 They have 
showed that genetic engineering of beta-cells using gp19K-and RID alpha/beta-
expressing lentiviral vectors can be a viable alternative to eliminate or reduce treatment 
with the potent immunosuppressive agents necessary at present for prolonged 
engraftment with transplanted islets. 
 
 
1.3.3. Adenoviral Vectors 
 
Adenoviruses are non-enveloped double- stranded DNA viruses, and can infect both 
dividing and non-dividing cells. Natural adenoviruses cause benign respiratory tract 
infection in humans. Their genome contains many genes and they do not integrate into 
the host DNA. Replication deficient adenoviruses can be generated by removing the E-1 
gene necessary for viral replication and replacing it with the gene of interest (for 
example, hepatocyte growth factor) and a promoter sequence.83 These recombinant 
viruses are replicated in cells that express the product of the E-1 gene and generated in 
high concentrations.84 
 
Cells infected with recombinant adenoviruses can express the therapeutic gene, but 
they cannot replicate as the genes needed for replication are absent. These vectors 
efficiently transduce cells and gene expression lasts for about 5-10 days. Therefore, Adv 
vectors are suitable for transient gene expression unlike retroviral vectors, which show 
long term expression. Adv vectors show extended duration of expression when given to 
nude mice or with an immunosuppressant indicating that the immune system may be 
responsible for the short duration of expression.85 
 
The immune reaction elicits both cell killing ‘cellular response’ and antibody 
producing ‘humoral response.’ Cellular response results in the killing of infected cells 
with T-lymphocytes, whereas the humoral response results in the production of 
antibodies to Adv proteins, resulting in the diminished transgene expression following 
subsequent infections.85,86 Moreover, most human beings are likely to have antibodies to 
Adv from previous infections as it is a commonly found virus infecting the human 
population. To address this problem, second generation of Adv vectors were produced 
where the other genes of the Adv genome are deleted like the E-3 gene required for 
eliciting immune response. However, their expression was not longer than 20-40 days.87 
 
Gutless Adv vectors are also generated in which all Adv genes are deleted. The viral 
DNA contains the start and end of the viral genome along with the viral packaging 
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sequence. They showed expression for about 84 days.88 However, the production of these 
gutless Adv vectors is somewhat difficult. Furthermore, they still have immunological 
problems, which need to be overcome for their in vivo applications. One way of getting 
around this problem is to develop strategies to target the viral particles to the required 
cells, tissues, or organs. Targeting of vectors can ideally lead to less immunological 
responses and fewer amounts of viral particles are needed to get the desired therapeutic 
effect. However, Adv vectors transduce cells more efficiently only in the presence of 
coxsackievirus and adenovirus receptors (CAR).89,90 Immune response from Adv vectors 
can further be attenuated by deleting E4 or a part of the E4 region. 
 
To target Adv vector to a specific cell or tissue usually Adv capsid, such as its fiber, 
protein IX (pIX), or hexon is altered. Of these, fiber proteins are the most studied. These 
proteins consist of a tail, shaft, and knob.91 The C-terminal knob is responsible for 
binding with CAR receptors.78,92 Targeting was achieved by incorporating an RGD 
peptide or a stretch of lysine residues (KKKKKKK [K7] peptide), targeting the αV 
integrins, or heparin sulfate proteoglycans into the HI loop or C-terminal region of the 
fiber knob.93-95 pIX can also be altered to achieve targeted delivery using an Adv vector.96 
pIX is a structural protein that sustains the structural integrity of the viral particles. 
Kurachi et al., reported the enhanced transduction efficiency of Adv vectors containing 
an RGD peptide in the c-terminus of pIX with α-helical spacer.91 Also modification of 
hexon containing RGD peptides (DCRGDCF) at HVR 5 region in the Ad vector can 
render them infective via αv- integrin receptor without any affinity to the CAR receptor.97 
Therefore, modifications in the Adv capsid at pIX or hexon containing heterologous 
peptides render them more selective as compared to that at fiber in the capsid.  
 
Biermann et al., have also shown that the modification of high-capacity Adv vectors 
by incorporating either 6X-His epitope or RGD peptide into the HI loop of the fiber knob 
rendered the vectors more effective and allowed efficient targeting towards different cell 
types.98 Targeting can also be achieved by affinity immobilization of Adv particles to the 
surfaces of biodegradable nanoparticles resulting in improved transduction through 
uncoupling cellular uptake from CAR receptor.99 The Adv nanoparticles containing 
inducible nitric oxide synthase (iNOS) inhibited growth of culture smooth muscle cells 
more compared to Adv encoding reporter gene GFP without any therapeutic activity 
(AdGFP) or Adv without any gene (Ad free vector). 
 
Islets are non-replicating cells which secrete insulin following an increase in blood 
glucose levels in the body. When there is death of islets due to genetic or immune 
mediated defects, one of the major alternatives is transplantation of islets. However, due 
to inadequate vascularization and subsequent immune attacks, islet transplantation did 
not achieve the success it was meant to. We have shown that human vascular endothelial 
growth factor (hVEGF) expression promotes new blood vessel formation and improves 
the outcome of islet transplantation.100 To enhance hVEGF gene expression, we 
transduced human islets with bipartite Adv vectors encoding hVEGF and human 
interleukin-1 receptor antagonist (hIL-1Ra) to promote revascularizaton and protect the 
human islets from apoptosis.101 Bipartite vector results in simplifying the amplification 
and purification of Adv vectors but also minimizes the Adv backbone for transduction, 
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thereby lessening the immunogenic effects of the vector. There was dose dependent 
increase in expression of hVEGF and hIL-1Ra from islets transduced with Adv-hVEGF-
hIL-1Ra. We confirmed whether the Adv vector is causing any detrimental effects to the 
islets by measuring the stimulation index of islets following transduction by Adv vector. 
Islets transduced by Adv vectors were as functional as untransduced islets. There was a 
decrease in caspase-3 levels in Adv transduced islets compared to untransduced islets 
when they were incubated with inflammatory cytokines. The expression was several 
times higher than the bicistronic plasmid vector phVEGF-hIL-1Ra. Following 
transplantation of Adv-hVEGF-hIL-1Ra transduced islets in non-obese diabetic severe 
combined immunodefecient (NOD-SCID) mice, there was a decrease in blood glucose 
levels and increase in insulin and c-peptide levels. 
 
Over-expression of hVEGF can be detrimental to islets and surrounding tissues and 
can lead to development of tumors.102,103 On the other hand hepatocyte growth factor 
(HGF) is a potent mitogen of human islets and is known to promote β-cell proliferation 
and is also anti-apoptotic.104 We therefore constructed a bipartite Adv vector encoding 
hHGF and hIL-1Ra (Adv-hHGF-hIL-1Ra) driven under a separate CMV promoter.101 
The vector showed increase in hHGF and hIL-1Ra genes with increase in multiplicity of 
infection (MOI) and duration. It did not affect the function of islets and showed 
decreased caspase-3 levels compared to the untransduced islets. Transduction of islets 
with Adv-hHGF-hIL-1Ra enhanced the level of Bcl-2 protein and inhibited the levels of 
Bax protein demonstrating the protective effect of hHGF and hIL-1Ra co-expression. 
There was also decrease in blood glucose levels and increase in insulin and c-peptide 
levels in NOD-SCID mice transplanted with Adv-hHGF-hIL-1Ra transduced islets. 
Immunohistochemcial staining of islet bearing kidney sections revealed stronger positive 
staining for human insulin, hHGF and hvWF suggesting more efficient blood vessel 
formation in Adv-hHGF-hIL-1Ra transduced islets. This shows that Adv vectors can be 
utilized for efficient and high expression of transgenes with less immunogenic effects 
compared to non-viral vectors. However, these vectors can still elicit immune responses 
more so in vivo setting. Therefore, by further removing the E4 or part of E4 genome of 
the Adv vectors and by selectively targeting the Adv vector to a specific organ or tissue 
by attaching a ligand (Gal-PEG) to it can further enhance the prospects of Adv vectors in 
gene therapy. 
 
 
1.3.4. Adeno-Associated Viral Vector  
 
Adeno-associated virus (AAV) is a simple non-pathogenic single-stranded DNA virus 
and is a member of parvoviridae family. AAV is composed of two open reading frames 
(ORF), rep and cap, and two inverted terminal repeats (ITRs) that define the start and end 
of the viral genome and packaging sequence,105 whereas the cap gene encodes viral 
capsid (coat) proteins and rep gene is for replication and integration. AAV requires 
additional genes to replicate, which are usually provided by an Adv or a herpes simplex 
virus (HSV). The AAV vector is produced by replacing the rep and cap genes with the 
transgene. Only one out of 100-1000 viral particles is infectious. Apart from the 
production of AAV vector being laborious, these vectors also have the drawback of 
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limited packaging capacity for the transgene (4.7kb). Furthermore, there are no packaging 
cells which can express all the proteins of the virus. Since rAAVs are deleted of viral 
genes, these vectors are less immunogenic. However, specific circulating bodies to 
rAAVs have been detected limiting their potential administration.106 
 
AAV vectors are the most promising vectors for gene therapy in improving islet 
transplantation outcomes mostly due to their low immunogenicity and high safety 
profile.107 AAV vectors are commonly used to deliver immunosuppressive genes to islets 
prior to transplantation resulting in improving the longevity and function of transplanted 
islets.108 Interleukin-10 (IL-10) gene was delivered to the islets using an AAV vector 
encoding IL-10 (AAV-IL-10) protected the islets from autoimmune recurrence and 
allogenic rejection.109 AAV-IL-10 mediated delivery of IL-10 mitigated the previously 
activated T-cells and protected the islets from immune rejection. 
 
 
1.3.5. Other Vectors  
 
HSV, which infects the cells of nervous system, is being developed as a vector. This 
virus contains 80 genes, of which one can be replaced to produce the vector.51 The use of 
recombinant baculoviruses, containing mammalian regulatory elements for efficient 
transient and stable transduction of different mammalian cell types is being explored.110 
Alpha viruses are being used in the development of vaccines.111,112 
 
 
1.4. Gene Delivery Systems 
 
Gene delivery systems help in controlling the location of a gene within the body by 
regulating the biodistribution of a gene expression system. They aid in protecting the 
gene expression systems from premature degradation in extracellular milieu and allowing 
non-specific or cell-specific targeting of the expression system. Some delivery systems 
are designed for specific targeting to a receptor or aid in intracellular trafficking of the 
gene expression system. Some of the common gene delivery systems used are discussed 
below. 
 
 
1.4.1. Liposomes 
 
Plasmids are generally complexed with cationic liposomes to protection them from in 
vivo degradation and to enhance intracellular delivery. Cationic lipids are composed of a 
hydrophobic lipid anchor group, linker group and a positively charged head group. 
Cationic lipids present in the liposome interact electrostatically with negatively charged 
phosphate backbone of DNA, thereby condensing the DNA into a more compact 
structure. These are most commonly used synthetic carriers for delivery of 
oligonucleotides, siRNAs, and plasmid DNA. The degree of transfection by cationic 
liposomes mainly depends on the extent of DNA condensation, cellular uptake by 
20 
interaction with biological surfaces and membrane fusion via transient membrane 
destabilization for cytoplasmic delivery avoiding lysosomal degradation. 
 
Although pH sensitive liposomes can be used to encapsulate DNA, low entrapment 
efficiency and high serum sensitivity limits their usage. This scenario changed with the 
introduction of the first cationic lipid 2, 3-dioleyloxypropyl-1-trimethyl ammonium 
bromide (DOTMA).113 Most of the research is being done to increase the transfection 
efficiency through the modification of the functional headgroups. Also, enhancing the 
transgene expression has become the focus of many studies. New cationic lipids were 
developed by modifying the headgroups of DOTMA resulting in increased transfection 
efficiency.((±)-N-(2-Hydroxyethyl)-N,N-dimethyl-2,3-bis(tetradecyloxy)-1-
propanaminium bromide (DMRIE), which was synthesized by modifying DOTMA 
showed increase in transfection efficiency and transgene expression. (3β (N-(N’,N’-
Bimethylaminoethane) carbamoyl) cholesterol (DC–Chol) was the first cholesterol based 
cationic lipid.114 Its structure was further modified by conjugating to polyamino groups 
resulting in more positive charges.114 Spermine and spermidine were conjugated to 
cholesterol to reduce cytotoxicity and increase the delivery of antisense 
oligonucloetides.61 Changing spermine or spermidine into a secondary amine showed 
better transfection efficiency both in vitro and in vivo.115 Some of the cationic lipids such 
as DC-Chol, DMRIE, and GL-67 have been used in early clinical trials, but the results 
were not encouraging. Hetreocyclic cationic lipids have also been studied for gene 
delivery. Some of these compounds showed better transfection abilities and lower 
cytotoxicity compared to cationic lipids with linear primary amines or polyamines as 
head groups.114 
 
Pyridinium-based cationic lipids have been shown to have similar or higher 
transfection efficiency compared to commercially available cationic lipid formulations. 
Pyridinuim lipids displayed higher transduction efficiency in cells which are not easily 
transfected by other cationic lipids like Lipofectin, and transfect relatively a large group 
of cells.116 Zhu et al., have synthesized a series of pyridinium lipids containing a 
heterocyclic ring and a nitrogen atom and prepared liposomes with co-lipid L-α 
dioleoylphosphatidylethanolamine (DOPE) and cholesterol (Chol) by sonication.117 
Pyridinium lipids with amide linker showed significantly higher transfection efficiency 
compared to their ester counterparts. Liposomes prepared at a 1:1 molar ratio of 
pyridinium lipid and a colipid showed higher transfection efficiency when either DOPE 
or cholesterol was used as a colipid to prepare liposomes. The pyridinium lipids with a 
trans-configuration of the double bond in the fatty acid chain showed higher transfection 
efficiency than its counterparts with cis-configuration at the same fatty acid chain length. 
In the presence of serum, C16:0 and lipofectamine significantly decreased their 
transfection efficiencies, which were completely lost at serum concentration of 30% and 
higher, while C16:1 trans-isomer still had high transfection efficiency under these 
conditions. 
 
The liposomal vector interacts with extracellular components in serum after in vivo 
administration. This often causes failure of the liposomal vector to reach the target cells. 
To have a targeted liposomal vector system, a ligand is required to bind to the receptor of 
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the target cells. Nasopharyngeal epidermal carcinoma cells which express excess of folate 
receptors were targeted by liposome-entrapped polycation-condensed DNA (LPDII) 
anionic liposome encapsulating polylysine condensed DNA tagged with folate.118 
Lys2Gal3, an aminogalactoside was used to target hepatoma in vitro119  which is a cationic 
formulation consisting of lipopolymaine, DOPE (helper lipid) and a galactolipid (DPPE-
Lys2Gal3). Lipososmal vectors have been used to improve the islet transplantation 
process. Hypoxia is one of the major factors resulting in primary non-function of 
transplanted islets. VEGF gene was delivered to the islets using a cationic lipid which 
increased the transfection efficiency and resulted in better glycemic control of the 
transfected islets.120 Tacrolimus was sufficiently encapsulated in liposomes and delivered 
to the islets resulting in improved immunosuppressive effect.121 However, toxicity at 
higher doses is a major concern. 
 
 
1.4.2. Cationic Peptides 
 
Major difficulties in non-viral delivery are the ability of the vectors to condense the 
DNA, targeting to specific cells, disrupt the endosomal membrane and deliver it to the 
nucleus. Peptide based vectors can be successfully employed to overcome these barriers. 
Cationic peptides condense DNA by interacting with its negatively charged phosphate 
backbone.  
 
Poly (L-Lysine) (PLL) is one of the first cationic peptides to deliver genes. However, 
increase in length of PLL leads to cytotoxicity. It shows very less transfection efficiency 
and needs another fusogenic peptide to facilitate plasmid release into the cytoplasm. 
Since PLL cannot escape from the endosome without addition of endoosmolytic agents 
such as chloroquine, Midoux and Monsingy have constructed a histidine-substituted 
polylysine, since histidine protonates at acidic pH in the endosome. Cationic peptides can 
be linked to cell specific ligands and bound to plasmids through electrostatic interaction. 
These complexes can interact specifically with target cell receptors leading to 
internalization of the complex into the cells. 
 
Synthetic peptides which are conjugated to lipids usually show better binding ability 
to DNA. For example, inclusion of dialkyl or diacyl chains in the cationic peptides 
improves their ability to bind to DNA and reduces aggregation of complexes in ionic 
media.9,31,122 Synthetic peptides derived from the N-terminus of influenza virus 
haemagglutinin and the rhinovirus VP-1 protein,123 or artificial amphipathic peptides 
were used.31 These peptides may have specificity for endosomal pH due to acidic 
residues (glutamic and aspartic acids) aligning on one side of an amphipathic helix. At 
neutral pH, the negatively charged carboxylic groups destabilize the alpha-helical 
structure resulting in the multimerization of peptides and/or membrane interaction. The 
pH specificity can be enhanced by introducing additional glutamic acids into the peptide 
sequence.124 The enhancement of gene expression is strongly dependent on the peptide 
sequence. The activity of cationic lipid/DNA complexes has been enhanced by mixing 
with Sendai virus envelopes. This approach and related systems utilizing neutral lipids 
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and liposome-like reconstituted envelopes (virosomes) based on Sendai virus or influenza 
viruses have been found effective for gene delivery.125 
 
Amphipathic cationic peptides such as, gramicidin S, is incorporated into a DOPE 
lipid/DNA composition to facilitate gene delivery. Incorporation of gramicidin S and 
DNA into asialofetuin-labeled liposomes was used for receptor-mediated gene delivery 
into primary hepatocytes.126 The influence of influenza virus-based peptides on cationic 
lipid-based transfection was studied.127 Wagner et al., showed that the use of positively 
charged lipospermine/DNA complexes resulted in 3 to 30-fold enhancement in gene 
expression by association with the peptides.128 Kamata et al., also showed that influenza-
derived peptides can increase the level of gene expression of a lipofectin formulation by 
up to five-fold.129 Thus, escape from endocytic vesicles does not seem to be a major 
barrier for optimized, positively charged DNA/lipospermine or lipofectin complexes. 
However, for less positively charged lipospermine complexes gene transfer efficiency 
was found to be increased by a factor of 50 to 1000 by synthetic peptides INF6 (influenza 
virus derived sequence) and INF10 (artificial sequence).128 Wilke et al., generated novel 
DNA complexes containing a palmitoyl-modified DNA-binding peptide showing 
enhanced transfection activity. Gene transfer was found to be restricted to mitotic cells.130 
 
Membrane-modifying peptides are able to enhance both lipofection and polyfection. 
Transfection efficiency of cationic peptide-based systems are strongly dependent on the 
presence of endosomolytic peptides or related agents (like glycerol, viral particles) which 
enhance cytoplasmic delivery.123 Transfection efficiencies can be improved up to more 
than 1000-fold by endosomolytic compounds.128  
 
It is important to determine (i) whether membrane-modulating peptides and DNA 
carriers can influence other intracellular steps beside endosomal escape or cell membrane 
fusion, such as the transport of the DNA into the nucleus of the cell; and (ii) whether the 
results obtained with membrane-active peptides in cell culture can also be exploited for in 
vivo gene transfer.125 Cationic peptides can be used for modifying the surface of islets to 
prevent inflammation mediated loss of islet function following islet transplantation. 
Teramura et al., modified the surface of islets was modified with a poly (ethylene 
glycol)-phospholipid conjugate bearing a biotin group (biotin-PEG-lipids, PEG 
MW:5000).131 This resulted in improved islet function as surface modification mitigated 
the blood mediated inflammation. 
 
 
1.4.3. Cationic Polymers and Lipopolymers 
 
Polyethyleneimine (PEI), polypropylenimine, and polyamidoamine dendrimers have 
been employed for gene delivery. PEI117 is a branched cationic polymer widely used in 
the gene delivery. It condenses the plasmids into colloidal particles that effectively 
transfect genes into a variety of cells in vitro.132 PEI contains several secondary amines 
which get protonated in the acidic environment of the endosome. This leads to endosomal 
swelling and subsequent membrane disruption leading to the release of the vector into the 
cytosol. However, high molecular weight PEI (>25 kDa) show cytotoxicity and 
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PEI/plasmid vector complexes under aggregation on storage, resulting in less gene 
expression. Chemical modification of low molecular weight PEIs may improve 
transfection and reduce cytotoxicity. 
 
Mahato and associates synthesized a water soluble lipopolymer by conjugating 
cholesteryl chloroformate to branched PEI of 1800 Da through primary and secondary 
amines.133 This polymer was non-toxic to CT-26 colon carcinoma cells and did not cause 
any aggregation compared to PEI/DNA complexes. Cholesterol will promote both 
micellar formation and hydrophobic interaction with plasmid and cellular membrane 
while PEI will condense DNA via electrostatic interaction. However, transfection of 
islets with lipofectamine showed less transfection efficiency as islets are approximately a 
cluster of 1000 non-dividing cells an new strategies are needed for improving the 
transfection efficiency.134 
 
 
1.4.4. Hybrid Vectors 
 
Both viral and non-viral vectors have their own advantages and disadvantages. There 
is much work going in developing new ways of better utilizing these vectors for gene 
expression and delivery. One such approach is to overcome the limitations of individual 
vectors by combining them. These vectors are called hybrid vectors. For example, the 
adenovirus hexon protein enhances the nuclear translocation and increases the transgene 
expression of PEI/pDNA complexes.135 PEG has been widely used for conjugating with 
adenoviral vector to prolong its circulation half-life, enhance transgene expression and 
prevent immune activation.136 
 
Cationic lipids and polymers may help in improving the transduction efficiencies of 
viral vectors. These are particularly useful in cells which do not have the specific viral 
receptors. The cationic nature of these molecules may promote binding to the negatively 
charged viral capsid altering the cell surface and allow internalization of viral particles. 
This can also elicit very less immunostimulation. For example, cationic liposomes 
promote delivery of Adv vectors into target cells which lack the CAR receptors and αv-
integrin receptors improving transgene expression.137 Diamond and his colleagues have 
showed that delivery of Adv vectors associated with dexamethasone-spermine (DS) 
conjugate to the lung enhanced targeting to the conducting airway epithelium and 
reduced immune response.138 Further, formulation of Adv encoding LacZ with DS/DOPE 
allowed re-administration of the adv vector, with little loss of transgene expression. 
 
Adv vector can also be coated with polymers bearing side chains containing 
positively charged quaternary amines and carbonyl thiazolidine-2 thione groups to 
prevent binding of Adv vector to plasma protein and consequently prolong blood 
circulation half-life and more deposition of the vector at diseased sites.139 
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1.4.5. Receptor-Mediated Gene Transfer 
 
Targeting ligands have been incorporated into DNA complexes for site or cell 
specific gene delivery.125 By attaching the DNA to a domain that can bind a cell surface 
receptor, such as the asialoglycoprotein receptor, transferrin receptor, the efficient 
cellular process of receptor-mediated endocytosis, can be utilized. Conjugates with 
polylysine, protamines, histones, PEI, cationic lipids, and other polycations have been 
generated and tested for receptor-mediated endocytosis. Hong and his colleagues used a 
hydroxycamptothecin (HCPT) loaded polyethylene glycol (PEG) niosomes attached with 
transferrin to the terminal group of PEG. This system showed high antitumor activity 
compared to non-transferrin bound niosomes.117 To enhance the uptake and specificity, 
Wu and Wu generated a polylysine-based, asialoglycoprotein receptor-specific gene 
delivery system by incorporation of asialoorosomucoid–polylysine conjugates into DNA 
complexes.140,141 Complexes could be efficiently delivered into endosomes or other 
internal vesicles of cells, but they were still separated from the cytoplasm by a 
membrane. This accumulation of complexes in internal vesicles strongly reduced the 
efficiency of gene transfer. Receptor-mediated delivery into a hepatocyte cell line 
resulted in uptake of DNA into practically all cells, but only a few cells expressed the 
delivered gene.142 
 
 
1.5. Concluding Remarks 
 
Although significant progress has been made to employ gene therapy in the clinic to 
treat various severe and debilitating diseases, there is still no FDA approved products in 
the market. This can be attributed to the lack of proper gene expression and delivery 
systems. While viral vectors efficiently transduce cells and have shown promise in their 
clinical trials, there are still some safety concerns, especially immunostimulation and 
integration within the host. Although non-viral vectors are relatively safe, transgene 
levels are very low and transient and thus many vectors have failed to perform well in the 
clinical trials. Therefore, efforts are being made to generate hybrid systems by combining 
the beneficial effects of non-viral and viral vectors. This has led to the significant 
enhancement in the gene expression, with minimal toxicity and immunogenicity. Further, 
the use of cellular promoters offers targeting of the vector to specific target tissues 
rendering the vector safe and efficacious. There is a definite need to develop targeting 
strategies for non-viral vectors which can compensate for the inefficient gene transfer. 
 
Islet transplantation usually results in decrease of hypoglycemic episodes which is a 
major drawback for conventional insulin therapy. Gene therapy has resulted in mitigating 
the hypoglycemic episodes and improved the graft function and showed higher levels of 
insulin and c-peptide levels in the majority of patients. However, this can last only for a 
few years after which patients have to resort to insulin therapy. Gene therapy can be 
implemented in this case to prevent the toxic effects of immunosuppressive agents and 
control the inflammation and immune reactions following islet transplantation. With 
recent improvements in gene delivery and increased understanding of the mechanisms 
25 
underlying graft failure, gene therapy for islet transplantation has the potential to move 
closer to the clinic as a treatment for patients with Type I diabetes. 
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CHAPTER 2. BIPARTITE VECTOR ENCODING hVEGF AND hIL-1Ra FOR EX 
VIVO TRANSDUCTION INTO HUMAN ISLETS 
 
 
2.1. Introduction 
 
Type I diabetes is an autoimmune disease that results in the destruction of insulin 
producing -cells of the pancreatic islets. Significant progress has been made in the field 
of islet transplantation where islets are transplanted via the portal veins of Type I diabetic 
patients. However, a large number of islet grafts do not secrete insulin, as they fail to 
revascularize upon transplantation and undergo apoptotic cell death.143 
 
Islets have an intricate microvasculature, which is disrupted during the isolation and 
purification process. Revascularization to the transplanted islets is known to improve the 
delivery of nutrients and oxygen to the inner core of islets leading to their 
survival.100,133,144,145 Transduction of islets with an adenoviral (Adv) vector encoding 
hVEGF or hepatocyte growth factor has been shown to promote the formation of new 
blood vessels, leading to improved islet survival.100,133,145,146 Apart from 
revascularization, islet grafts also need to be protected from apoptosis induced by 
inflammatory cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-alpha 
(TNF-α) and interferon-γ (IFN-γ) released from resident macrophages and infiltrating 
immune cells at the transplantation site.147 Immunosuppressive medications are used 
simultaneously to protect transplanted islets, but reports of severe side effects induced by 
immunosuppressive drugs have prompted attention on developing ways to reduce their 
toxicities.148 Among various cytokines, IL-1β plays a key role in apoptotic cell death. 
Inhibition of IL-1β receptor binding using interleukin-1receptor antagonist (IL-1Ra) 
resulted in improved islet survival and function.149-151 
  
Considering the favorable uses of hIL-1Ra and hVEGF, we recently constructed a 
plasmid vector encoding these two genes (phVEGFhIL-1Ra) by cloning hIL-1Ra under 
the cytomegalovirus (CMV) promoter and hVEGF under the elongation factor-1R(EF-
1R) promoter in pBudCE4.1 vector, and demonstrated dose and time dependent 
expression of hVEGF and hIL-1Ra at after transfection.18 Since transfection efficiency of 
this bipartite plasmid into human islets was very low and the better known transduction 
efficiency of Adv vectors, in this study, we constructed a bipartite Adv vector encoding 
hVEGF and hIL-1Ra driven by separate CMV promoters. The use of bipartite vector 
encoding these genes not only simplifies the amplification and purification process of 
Adv vectors but also decreases the use of total Adv backbone for transduction, which is 
expected to minimize immunogenic and toxic effect of Adv vectors. We determined 
transduction efficiency, islet function and caspase-3 release upon incubation with 
inflammatory cytokine cocktail of TNF-α, IL-1β and IFN-γ. We then transplanted islets 
under the kidney capsules of NOD-SCID mice after transduction with Adv-hVEGF-hIL-
1Ra and determined the blood glucose, insulin and c-peptide levels. Finally, the islet 
bearing kidney sections of these diabetic mice were stained for human insulin, hVEGF 
and von Willebrand factor (hvWF). 
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2.2. Materials and Methods 
 
 
2.2.1. Materials 
 
Agarose, tris-borate-EDTA buffer, goat serum, glucose and haematoxylin solution 
were purchased from Sigma-Aldrich Co. (St. Louis, MO). Fetal bovine serum (FBS) and 
CMRL-1066 media were purchased from MediaTech Cellgros (Herndon, VA). Human 
VEGF and IL-1Ra ELISA kits and cytokines IL-1β, TNF-α, and IFN-γ were purchased 
from R&D Systems (Minneapolis, MN). Human Insulin ELISA kits were purchased from 
Alpco Diagnostics (Windham, NH), and RNA extraction and Caspase-Glo 3/7 assay kits 
from Promega (Madison, WI). SYBR Green real time PCR master mix and reverse 
transcription reagents were purchases from Applied Biosystems (Foster City, CA). 
 
 
2.2.2. Methods 
 
The methods used in this study are described below. 
 
 
2.2.3. Construction of Adv-hVEGF-hIL-1Ra 
 
A bipartite Adv vector encoding hVEGF and hIL-Ra genes was constructed with the 
help of OD 260, Inc. (Boise, ID). Briefly, hIL-1Ra cDNA along with rabbit β-globin 
polyA was cloned into pE3.1 shuttle plasmid, while hVEGF fragment along with rabbit 
β-globin polyA was inserted into pE1.2 shuttle plasmid. The pE3.1-hIL-1Ra plasmid was 
further modified by removing the intron adjoining CMV promoter. These plasmids were 
transformed in super competent TOP 10 cells and amplified in terrific broth media. 
pE1.2-hVEGF and pE3.1-hIL-1Ra were digested to excise these expression cassettes for 
ligation with SfiI digested AdenoQuick 13.1 plasmid simultaneously using T4 DNA 
ligase overnight at 16ºC. The ligated products were packaged into phage lambda particles 
using MaxPlax packaging extract (Epicentre, Madison, WI). The packaging mixture was 
used to infect E.coli XL-1Blue (Stratagene, La Jolla, CA) and clones were selected on LB 
supplemented with 25µg/ml kanamycin and 50µg/ml ampicillin. The Pac I linearized 
cosmid was transfected into 293 cells to rescue the virus. Three viral plaques were 
amplified, and their genomic DNAs were extracted. The presence of hVEGF and hIL-
1Ra expression cassettes was confirmed by restriction analysis with Hind III and Not I. 
The clone containing the two genes was transduced to 293 cells, and the viral extract was 
further transduced into 293 cells, amplified and purified on two CsCl gradients. The 
bands harvested were dialyzed against GTS buffer (25% glycerol, 25mM NaCl, 20mM 
Tris-HCl, pH 8) and viral suspension was collected, filtered and stored at -70ºC. Once the 
construction was confirmed for the insertion of genes hVEGF and hIL-1Ra, the virus was 
tested for expression of these genes in vitro and then in vivo. 
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2.2.4. Determination of Viral Titer 
 
The following methods were used to calculate the viral titer. 
 OD 260-SDS Method: Adv-hVEGF-hIL-1Ra was purified using CsCl density 
gradient. The purified virus was diluted at different concentrations in the 
range of 0.1-1.0 in 0.1% sodium dodecyl sulfate (SDS) buffer. The 
absorbance was recorded at 260nm. The viral titer was calculated based on the 
extinction coefficient of 1.1X1012 virus particles (VP) per Abs260 unit in the 
presence of SDS buffer.  
 Plaque Assay: Freshly confluent 6cm dishes seeded with 293 cells were 
infected with various dilutions of Adv-hVEGF-hIL-Ra. Three days later, the 
cells were split into 10cm dishes to boost virus plaque formation. The cells 
were split again into 15cm dishes 10 days later. The formation of virus 
plaques was monitored up to 3 weeks after which the infection titer was 
calculated.  
 Infectious Viral Titers: The infectious viral titer was also determined by using 
an Adeno-X rapid titer kit from Clontech. Different dilutions of Adv-hVEGF-
hIL-1Ra was taken and transduced to AD-293 cells, using untransduced cells 
as a control. After 48h post-transduction, AD-293 cells were fixed and 
incubated with Anti-hexon antibody, followed by a secondary horse radish 
peroxidase (HRP)-conjugated antibody. Then the cells were stained with 3, 3’ 
diaminobenzidine tetrahydrochloride (DAB) substrate and positively stained 
cells were counted under a microscope, and the titer was determined.  
 
 
2.2.5. Islet Culture and Transduction  
 
Human islets were received from one of the several Islet Cell Resource (ICR) Centers 
in culture media at 4°C. On receiving, the islets were cultured in CMRL-1066 medium 
containing 10% fetal bovine serum (FBS) and 1% Penicillin Streptomycin. Islets were 
then transduced with Adv-hVEGF-hIL-1Ra, while non-transfected islets as well as the 
islets transfected with phVEGF-hIL-1Ra/Lipofectamine complexes (3/1, +/-, 2.5µg 
DNA/1000 islets) were used as controls. To determine the optimal multiplicity of 
infection (MOI) of Adv vectors in terms of plaque forming units (pfu) per cell of an islet 
which is a cluster of 1000 cells, 1000 islets were incubated with Adv-hVEGF-hIL-1Ra in 
300μl media in a 96 well plate for 12h, followed by washing and further culturing in 1ml 
of media in 24-well plates. Gene expression was determined at day 1 and 3 by 
quantifying secreted protein in the media by ELISA (R&D Systems). Total protein of the 
islet cell extracts was also determined using the bicinchoninic acid (BCA) protein assay 
kit.  
 
 
2.2.6. Quantitative Real time PCR  
 
To determine hVEGF and hIL-1Ra gene expression 3 days after transduction with 
Adv-hVEGF-hIL-1Ra, the islet pellet was collected for isolation of total RNA using 
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RNAeasy mini isolation kit from Promega. Two hundred and fifty nanograms (ng) of 
extracted RNA was converted into cDNA using MultiScribe reverse transcriptase and 
random hexamers (Applied Biosystems, Inc.) by incubation at 25°C for 10 min, followed 
by reverse transcription at 48°C for 30 min and enzyme inactivation at 95°C for 5 min. In 
all 3.85μl of cDNA was amplified by real time RT-PCR. To determine the level of 
hVEGF expression due to Adv-hVEGF-hIL-1Ra transduction, while excluding the 
endogenous expression, Adv vector specific reverse primer (5’-TAG CCA GAA GTC 
AGA TGC TCA AGG-3’) was designed from the PolyA region specific to the vector. 
The forward primer (5’-TTT CTG CTG TCT TGG GTG CAT TGG-3’) was designed 
from the hVEGF gene sequence. We also designed both primers from the gene: forward 
(5’-TTT CTG CTG TCT TGG GTG CAT TGG-3’) and reverse (5’-AAG ATG TCC 
ACC AGG GTC TCG AAT-3’) so that cumulative expression of hVEGF can be 
determined. 
 
In case of hIL-1Ra both, forward (5’-ATC CAG CAA GAT GCA AGC CCT-3’) and 
reverse (5’-TTC GTC AGG CAT ATT GGT GAG GCT-3’) primers were designed from 
the gene sequence (NCBI Accession#AK290898). To determine the level of hIL-1Ra 
expression excluding its endogenous expression, forward primer was designed from the 
Adv sequence (5’-AGC CTC ACC AAT ATG CCT GAC GAA-3’) and reverse primer 
from the gene sequence (5’-TTG CCA TGC AAG AAT GGG AAC AGG-3’) (NCBI 
Accession#AB021221). The PCR conditions included denaturation at 95°C for 10 min, 
followed by 40 cycles of amplification by sequential denaturation at 95°C for 15 sec and 
primer annealing as well as strand extension for 1 min. 
 
To confirm the amplification specificity, the PCR products were subjected to melting 
curve analysis. hVEGF and hIL-1Ra gene expression was normalized to 18s rRNA as 
internal control. Threshold cycle number was compared between Adv-hVEGF-hIL-1Ra 
with the same parameters using non-transfected islets as controls.  
 
 
2.2.7. In Vitro Islet Function after Transduction  
 
The in vitro islet function after transduction with Adv-hVEGF-hIL-1Ra was 
determined by the static incubation method, using non-transduced islets as control. 
Transfection media was removed and the islets were sequentially incubated at 37ºC for 
1h in the media containing 2.5mM (basal) and 22mM glucose (stimulated). After 
incubation, supernatants were collected and analyzed for insulin release by ELISA 
(Alpco Diagnostics). Insulin secretion was expressed as µU/ml and the ratio of insulin 
levels at 22mM to 2.5mM glucose was used to calculate the stimulation index. 
 
 
2.2.8. Cytoprotective Effect of Adv-hVEGF-hIL-1Ra 
 
One thousand islets per well of 96 well plates were transduced with 1000 MOI of 
Adv-hVEGF-hIL-1Ra, Adv-hVEGF or Adv-hIL-1Ra. At 12h post-transduction, islets 
were washed and incubated with either fresh media or a cocktail of IL-1β (10ng/ml), 
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TNF-α (10ng/ml) and IFN-γ (50ng/ml). At day 3 post transduction islets were collected 
from each well and lysed with lysis buffer to measure the caspase-3 concentration using 
the Caspase-Glo 3/7 Assay kit (Madison, WI). 
 
We also determined the cytoprotective effect of Adv-hVEGF-hIL-1Ra on islet 
viability by fluorescence microscopy of islets after transduction with Adv-hVEGF-hIL-
1Ra (500, 1000 and 2000 MOI), Adv-hVEGF (1000 MOI), and Adv-hIL-1Ra (1000 
MOI) for 12h, followed by incubation with the cytokine cocktail for 3 days. These islets 
were stained with propidium iodide (500nM) to identify dying or dead cells under 
fluorescence microscope (Olympus). 
 
 
2.2.9. Islet Transplantation Studies 
 
Animal experiments were performed as per the NIH 
(http://grants1.nih.gov/grants/olaw/ references/phspol.htm) and institutional animal care 
and use guidelines using approved protocols. To establish the diabetic animal model, 
streptozotocin (STZ) (40mg/kg) was administered to NOD-SCID mice by intraperitoneal 
injection for 5 consecutive days. Animals were considered to be diabetic after two 
consecutive blood glucose measurements≥325mg/dl using a One Touch Ultra 
Glucometer (Lifescan, Milipitas, CA). Before transplantation, human islets were 
transduced by Adv-hVEGF-hIL-1Ra or Adv-LacZ at the dose of 1000 MOI for 12h and 
washed with PBS. About 1500 transduced or non-treated islets were transplanted under 
the left kidney capsules of diabetic mice. The nonfasting glucose levels were measured 
up to 20 days post-transplantation. The mice were then anesthetized to collect blood to 
measure serum insulin by ELISA and C-peptide by radioimmunoassay (Diagnostic 
Products Corp.). The graft-bearing kidneys were removed to confirm the function of islet 
grafts by the return to blood glucose levels to325mg/dL for two consecutive days. 
 
 
2.2.10. Immunohistochemistry and Morphometric Analysis 
 
To determine hVEGF expression and angiogenesis, transplanted mice were 
sacrificed, kidneys were isolated, washed with PBS, fixed in 4% formaldehyde overnight, 
and embedded in paraffin as described before.133 Sections of 5-7µm thickness were cut 
and immunostained with rabbit anti-insulin, hVEGF and hvW primary antibodies, 
respectively. The immunoreactivity was detected using goat anti-rabbit IgG, H&L chain 
specific peroxidase conjugate and subsequent incubation with DAB substrate. For 
morphometric analysis, hVEGF and hvWF-positively immunostained color (brown in 
each case) was selected for quantification of the relative intensity using NIH Image 1.62 
software to determine the mean values, which were subsequently compared between 
Adv-hVEGF-hIL-1Ra transduced and control islet transplanted diabetic recipient mice. 
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2.2.11. Statistical Analysis 
 
Statistical significance of the difference between the two groups was determined by 
unpaired t-test and between several groups by one-way ANOVA. 
 
 
2.3. Results 
 
The results of the study are discussed below. 
 
 
2.3.1. Construction of Adv-hVEGF-hIL-1Ra 
 
Adv-hVEGF-hIL-1Ra is a serotype 5 based replication deficient Adv vector that 
contains a CMV promoter, hVEGF cDNA and rabbit β-globin polyA in the E-1 region 
and a CMV promoter, hIL-1Ra cDNA and rabbit β-globin polyA in the E-3 region 
(Figure 2-1). Both cassettes are oriented from left to right relative to the adenovirus 
genome and lack the CMV intron that was present in the cosmid pADhVEGF-hIL-1Ra, 
from which no virus could be recovered. hVEGF and hIL-1Ra coding sequences and 
polyA signals were placed under the control of a separate CMV promoter cloned into 
pE1.2 and pE3.1. The resulting vectors were combined in Adenoquick 13.1 to generate a 
cosmid that contains the entire sequence of recombinant adenovirus. The presence of 
hVEGF and hIL-1Ra expression cassettes in these vectors was confirmed by restriction 
digestion with Hind III and NotI. The number of viral particles in the stock solution of 
Adv-hVEGF-hIL-1Ra was determined by OD260–SDS method. This gives the total 
number of 1.2X1012 viral particles per ml of the stock solution irrespective of their plaque 
forming ability. The infectious titer of Adv-hVEGF-hIL-1Ra (8X1010 IU/ml) was 
calculated by plaque assay method. This was further ascertained by performing the 
adenotiter assay using an Adeno X rapid titer kit and the titer was calculated to be 6X109 
ifu/ml (infectious units/milliliter). We used infectious units/ml viral titer for all the 
experiments.  
 
 
2.3.2. Transduction Efficiency of Adv-hVEGF-hIL-1Ra 
 
Following transduction of islets with Adv-hVEGF-hIL-1Ra, the level and duration of 
hVEGF and hIL-1Ra proteins increased with increase in MOI. hVEGF and hIL-1Ra 
protein levels at day 3 post-transduction was over 100 times more than that of the 
untransduced islets (Figure 2-2), indicating that Adv-hVEGF-hIL-1Ra transduction 
would lead to high local concentrations of hVEGF and hIL-1Ra in the immediate vicinity 
of islets post transplantation. We also transfected islets with the bipartite plasmid DNA 
encoding these two genes (phVEGF-hIL-1Ra) after complex formation with 
Lipofectamine, which produced about 100 times lower levels of hVEGF and hIL-1Ra 
proteins than that of the islets transduced with Adv-hVEGF-hIL-1Ra (Figure 2-2). 
 
We also determined hVEGF and hIL-1Ra gene expression by real time RT-PCR. The 
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Figure 2-1 Construction of E1 and E3 deleted Adv-hVEGF-hIL-1Ra. 
 
Construction of E1 and E3 deleted bipartite Adv vector by cloning hVEGF and hIL-
1Ra into the multiple cloning sites of shuttle plasmids pE3.1 and pE1.2. These expression 
cassettes were cloned into AdenoQuick plasmid 13.1 to generate a cosmid containing the 
entire sequence of recombinant adenovirus. After transfection into 293 cells, Adv-
hVEGF–hIL-1Ra was produced. 
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Figure 2-2 Time profile of hVEGF and hIL-1Ra at protein levels. 
 
Time profile of hVEGF and hIL-1Ra gene expression at protein levels in human islets 
transduced Adv-hVEGF-IL-1Ra at different multiplicities of transduction (MOI) 100, 
500, 1000, 2000 and 5000 per 1000 islets. Non-transfected islets as well as the islets 
transfected with phVEGF-hIL-1Ra/Lipofectamine complexes (3/1, +/-, 2.5µg DNA/1000 
islets) were used as controls. ELISA of cell culture supernatants were performed at days 
1 and 3. Cumulative expression levels were presented as the mean±S.D. of n=4. *p<0.05 
compared with untransduced islets using ANOVA. 
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normalized mRNA concentration to that of the control was significantly increased with 
increase in MOI of Adv-hVEGF-hIL-1Ra (Figure 2-3). Gene expression at mRNA level 
of hVEGF and hIL-1Ra was more than 100 times higher than that of untransduced islets. 
Islets transfected with the bipartite plasmid, phVEGF-hIL-1Ra, also produced very low 
levels of hVEGF and hIL-1Ra mRNA. Each graph is indicative of the relative increase in 
expression of hVEGF and hIL-1Ra independently. This shows that Adv-hVEGF-hIL-1Ra 
can simultaneously express both genes with high efficiency. The mRNA levels of 
hVEGF and hIL-1Ra obtained by using one primer from the gene and the other from the  
Adv backbone showed dose dependent increase signifying that these genes were being 
expressed by Adv-hVEGF–hIL-1Ra (data not shown). The mRNA concentrations of each 
gene were normalized to that of the untransduced islets. The amplification specificity was 
confirmed by melting peak analysis, which showed a single predominant peak each for 
18s (85.4°C), hVEGF (84.5°C) and hIL-1Ra (87.05°C), respectively (data not shown). 
 
 
2.3.3. Effect of Viral Transduction on Islet Function 
 
To determine whether insulin secretion was adversely affected by transduction of 
islets with Adv-hVEGF-hIL-1Ra, insulin secretion in response to glucose challenge was 
carried out at day 5 post-transduction. Glucose challenge was determined by quantifying 
glucose stimulated insulin release at basal level (2.5mM) and stimulated (22mM) glucose 
concentrations. As shown in Figure 2-4 stimulation index was almost identical to that of 
untransduced islets when 1000 islets were treated with Adv-hVEGF-hIL-1Ra at the dose 
of 1000 MOI. However, when 1000 islets were treated with this vector at 2000 MOI, 
there was some cytotoxicity resulting in decreased stimulation index. 
 
 
2.3.4. Apoptosis of Islets 
 
Apoptosis of islets leading to their impaired function and subsequent death is an 
important detriment to islet transplantation. Caspase-3 plays a major role in the apoptosis 
of islets. Therefore, we determined caspase-3 level in the islets transduced with Adv-
hVEGF-hIL-1Ra and incubated with a cocktail of inflammatory cytokines such as IL-1β, 
TNF-α and IFN-γ. Caspase-3 activity was very high in the un-transducted islets treated 
with the cytokine cocktail compared to that in the absence of the cytokine cocktail 
(Figure 2-5). The islets treated with 1000 and 2000 MOI Adv-hVEGF-hIL-1Ra and Adv-
hIL-1Ra showed significantly lower levels of caspase-3 activity compared to the 
untransduced control islets or the islets transducted with Adv-hVEGF at 1000 MOI and 
incubated in the cytokine cocktail (Figure 2-5). In contrast, caspase-3 activity of all 
groups was very low when these islets were not incubated with the cytokine cocktail, 
suggesting that the Adv vector was non-toxic to islets at these tested doses. 
 
We also determined the cytoprotective effect of Adv-hVEGF-hIL-1Ra on islet 
viability by fluorescence microscopy after transduction and incubation with the cytokine 
cocktail. These islets were stainied with propidium iodide, which is known to be  
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Figure 2-3 Real time PCR of islets transduced with Adv-hVEGF-IL-1Ra. 
 
Real time PCR of human islets at day 3 post transduction with Adv-hVEGF-IL-1Ra 
at MOI of 100, 500, 1000, 2000 and 5000. Forward and reverse primers were designed 
from hIL-1Ra and hVEGF genes. Non-transfected islets as well as the islets transfected 
with phVEGF-hIL-1Ra/Lipofectamine complexes (3/1, +/-, 2.5µg DNA/1000 islets) were 
used as controls. Cell pellet was collected at day 3 and processed for mRNA extraction, 
reverse transcription and real time PCR using SYBR green chemistry. The normalized 
mRNA values of the different MOI treated islets are plotted. Since different primers were 
used, no direct comparison can be made, other than demonstration of increase in mRNA 
levels with increase in MOI. Results are expressed as the mean S.D of n=4 *P<0.05 
compared with control using ANOVA. 
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Figure 2-4 Glucose Stimulation Index.  
 
Stimulation indexes (SI) of human islets with or without cytokine incubation after 
transduction with Adv-hVEGF-IL-1Ra. Non-transduced (N) islets were used as controls. 
Results are expressed as the mean±S.D of n=3. *P value compared to untransduced islets. 
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Figure 2-5 Effect of Adv-hVEGF-hIL-1Ra expression on caspase-3 activity. 
 
Caspase-3 activity in human islets in the absence of or after incubation with the 
cytokines was determined by measuring the amount of caspase-3 present in the lysate of 
islets after cell lysis using a Caspase-Glo 3/7 luciferase assay. The islets were transduced 
with Adv-hVEGF-hIL-1Ra, at Adv-hVEGF or Adv-hIL-1Ra prior to incubating with 
cytokines IL-1β (10ng/ml), TNF-α (10ng/ml) & INF-γ (50ng/ml). Non-transduced islets 
were used as control. Mean±S.D. of n=3, *p value compared with cytokine treated non-
transduced islets using ANOVA. 
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excluded by viable cells but can penetrate cell membranes of dying or dead cells, as 
evidenced red staining. As shown in Figure 2-6, the number of red cells was significantly 
lower in all the groups which were not incubated with the cytokine cocktail. However, 
incubation with the cytokine cocktail significantly increased the number of red cells in 
case of untransduced control islets. However, transduction of islets with Adv-hVEGF-
hIL-1Ra and Adv-hIL-1Ra significantly decreased the number of red cells even after 
incubation with the cytokine cocktail, suggesting the protective effect of hIL-1Ra gene 
expression. These results corroborate well with the results shown in Figure 2-5 for the 
effect of Adv-hVEGF-hIL-1Ra on caspase-3 activity. 
 
 
2.3.5. Islet Survival and Function after Transplantation 
 
The effect of hVEGF and hIL-1Ra gene expression on the islet survival and function 
post-transplantation of 1500 islets transduced with Adv-hVEGF-hIL-1Ra at 1000 MOI 
under the kidney capsules of NOD-SCID mice was determined in terms of blood glucose, 
human insulin, and C-peptide levels. Diabetes was partly corrected in higher number of 
mice receiving Adv-hVEGF-hIL-1Ra transduced islets as compared to those receiving 
Adv-LacZ transfected and non-treated islets. Adv-hVEGF-AdvhIL-1Ra transduced islets 
showed much rapid reduction in blood glucose levels to220mg/dl (3 days) than Adv-
LacZ transduced or non-treated islets. Mice transplanted with Adv- hVEGF-hIL-1Ra 
transduced islets had the lowest blood glucose levels, followed by non-treated islets 
(Figure 2-7A). Blood glucose levels returned to325mg/dL upon removal of the islet 
graft-bearing kidney at days 21 after transplantation, confirming that transplanted islets 
were functional. Upon glucose challenge, both blood insulin and C-peptide levels were 
significantly higher in mice transplanted with Adv-hVEGF-hIL-1Ra transduced islets 
compared to all the other groups, indicating better islet engraftment and function  
(Figure 2-7B, C). These results suggest that compared to non-treated or Adv-LacZ 
transduced islets, co-expression of hVEGF and hIL-1Ra reduced the blood glucose level 
of mice, and increased the level of blood insulin and c-peptide upon glucose challenge. 
 
 
2.3.6. Immunohistochemistry  
 
To determine whether hVEGF gene expression after transduction with Adv-hVEGF-
hIL-1Ra will promote angiogenesis by human islets, we isolated the kidney bearing Adv-
hVEGF-hIL-1Ra transduced islets at 20 days post-transplantation into diabetic NOD-
SCID mice for sectioning and staining with polyclonal rabbit hVEGF and vonWillebrand 
Factor (hvWF) antibodies. Staining with anti-human insulin and untransduced islet 
sections were used as the controls. The positive staining of hVEGF was higher in the 
transduced islets compared to untransduced islets (Figure 2-8), suggesting efficient 
hVEGF gene expression after transduction with Adv-hVEGF-hIL-1Ra. The positive 
staining of hvWF factor was more evident in Adv-hVEGF-hIL-1Ra transduced islets, 
which is an indicator for endothelial cells. Morphometric analysis revealed that Adv-
hVEGF-hIL-1Ra transduced Islet grafts exhibited higher hVEGF and hvWF-
immunostaining and intensity than control islet grafts, with relative intensities of 1.45 vs. 
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Figure 2-6 Effect of hVEGF and hIL-1Ra co-expression on islet viability. 
 
Effect of hVEGF and hIL-1Ra co-expression on islet viability was examined under 
fluorescence microscopy after propidium iodide staining of intact islets transduced with 
Adv-hVEGF-hIL-1Ra, Adv-hIL-1Ra and Adv-hVEGF, and then incubated for 3 days 
with inflammatory cytokines. Red staining represents cell membranes of dying or dead 
cells. 
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Figure 2-7 Transplantation of Adv-hVEGF-hIL-1Ra transduced islets. 
 
Following transduction with Adv-hVEGF-hIL-1Ra at 1000 MOI, 1500 islets were 
transplanted under the kidney capsule of streptozotocin-induced diabetic NOD-SCID 
mice. The mice transplanted with Adv-LacZ-transduced and non-transduced islets were 
used as controls. A) The nonfasting glucose levels were measured in each animal up to 20 
days post-transplantation using a One Touch Ultra Glucometer. Blood glucose levels 
returned to325mg/dL upon removal of the islet graft-bearing kidney at days 21 after 
transplantation. B&C). At day 21 post-transplantation, the mice were sacrificed and blood 
was collected to measure serum insulin by ELISA and C-peptide by radioimmunoassay 
(RIA). Data are presented as the mean+S.D. of n=4, *p<0.5, compared to Adv-hVEGF-
hIL-1Ra transduced islet group. 
41 
Insulin hVWVEGF
A B C
D E F
 
 
 
Figure 2-8 Immunohistochemical staining of islet bearing kidney sections. 
 
Immunohistochemical staining of islet bearing kidney sections at day 20 post-
transplantation of human islets transduced with Adv-hVEGF-hIL-1Ra at 1000 MOI. 
Rabbit polyclonal anti human VEGF and hvW were used for detecting human VEGF and 
endothelial cells. These pictures were taken at x40 magnification. A) Insulin, B) hVEGF 
and C) vWF staining for the islets transduced with Adv-hVEGF-hIL-1Ra; and D) insulin, 
E) hVEGF and F) hvWF staining for the control islets.  
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1 for hVEGF and 1.30 vs. 1 for hvWF, respectively. To correlate the degree of islet 
revascularization with the islet mass in the kidney capsule, we also stained for human 
insulin. Adv-hVEGF-hIL-1Ra transduced islets displayed significantly higher levels of 
insulin content than control islet groups (Figure 2-8B), with relative intensity of 1.3 vs. 1. 
This quantitative difference in insulin content in the kidney capsule between Adv-
hVEGF-hIL-1Ra transduced and control islet groups of diabetic recipient mice correlated 
well with their blood glucose, serum insulin and c-peptide profiles (Figure 2-7). The 
positive staining for human insulin also confirmed the functionality of islets. These 
results indicate the beneficial effect of Adv-hVEGF-hIL-1Ra for the islet survival and 
function post-transplantation. 
 
 
2.4. Discussion 
 
Isolation and purification of islets disrupt their microvasculature, leading to hypoxia 
and apoptosis upon transplantation.133 We and others have shown that hVEGF expression 
promotes new blood vessel formation and improves the outcome of islet 
transplantation.18,133 However, effective prevention of islet destruction after 
transplantation requires not only revascularization but also abrogation of cytokine 
mediated islet cell death and dysfunction. Islet injury stimulates resident macrophages 
and infiltrating leukocytes to produce cytotoxic cytokines like IL-1β, TNF-α and IFN-γ.  
 
Among these cytokines, IL-1β is the key mediator of β cell destruction. 
Administration of recombinant IL-1Ra protein has been shown to prevent islet 
dysfunction upon transplantation.151 Ex vivo transduction of human islets with Adv-hIL-
1Ra has been reported to prevent IL-1β induced β cell impairment and activation of islet 
cell apoptosis.150 Therefore, we recently transduced human islets with a mixture of Adv-
hVEGF and Adv-hIL-1Ra133 and demonstrated suppression of cytokine induced iNOS 
gene expression and NO production.133,152 Similarly, Bertera et al.,153 reported synergistic 
effect after simultaneous Adv transduction of mouse islets with two individual genes, 
such as IL-1Ra and indoleamine 2, 3 dioxygenase or hIL-1Ra and manganese superoxide 
dismutase (MnSOD). 
 
The objective of this study was to evaluate a bipartite Adv vector for multiple gene 
delivery to human islets for promoting revascularization and inhibiting inflammatory 
cytokine–mediated destruction. There are several studies where bipartite Adv vectors 
have been constructed with one therapeutic gene and another marker gene, especially 
green fluorescence protein (GFP).154,155 In this study, we have constructed a replication 
deficient bipartite Adv vector encoding hVEGF and hIL-1Ra. The use of bipartite vector 
not only simplifies the amplification and purification process of Adv vectors, but also 
decreases the use of total Adv backbone. This is expected to minimize the immunogenic 
and toxic effects of Adv vectors. hVEGF is known to promote angiogenesis156 and 
improved vascularization can lead to reduced apoptosis. On the other hand, hIL-1Ra 
inhibits apoptosis of islets.151 Apoptosis begins during the islet isolation process, peaks 2-
3 days post transplantation, and continues for approximately 7~14 days until what 
remains of the graft has stabilized and become vascularized. Therefore, the use of 
43 
replication deficient Adv vectors is appropriate. We decided to use ∆E1 and ∆E3 Adv 
vector because our goal was to achieve transient gene expression, while avoiding other 
potential side effects and in vivo virus replication. To determine hVEGF and hIL-1Ra 
gene expression, we first transduced human islets with Adv-hVEGF-hIL-1Ra and then 
monitored transgene expression for 3 days. hVEGF and hIL-1Ra expression over days 1 
and 3 showed considerable increase (Figure 2-2), suggesting the efficacy of Adv-hVEGF-
hIL-1Ra. Variation in MOI, promoters and duration of the incubation time are known to 
affect the transfection efficiency of Adv vectors in various cell types. Therefore, we 
sought to optimize the transduction conditions of human islets with Adv-hVEGF-hIL-
1Ra. hVEGF and hIL-1Ra gene expression increased with increase in MOI from 100 to 
5000. However, we decided to infect 1000 islets with this vector at 1000 MOI to avoid 
any toxic side effects. Unlike the Adv vector, transfection with the bipartite plasmid 
encoding hVEGF and hIL-1Ra (p-hVEGF-hIL-1Ra) produced very little hVEGF and 
hIL-1Ra (Figure 2-2) which is consistent with our previous results18 and is expected since 
an islet is a cluster of 200-1000 cells and difficult to transfect. 
 
Since prolonged incubation with Adv vectors may induce apoptosis and loss of 
endothelial cells; we decided not to co-culture the islets beyond 12h. We then determined 
hVEGF and hIL-1Ra gene expression at mRNA level for which we used 18s as an 
internal control. The mRNA levels of hVEGF and hIL-1Ra increased with increase in  
MOI (Figure 2-3), indicating the Adv vector is indeed expressing these two genes as 
desired. Although hVEGF and hIL-1Ra increased at both protein and mRNA levels with 
increase in the Adv MOI, these results cannot be directly correlated. Unlike ELISA, we 
used different primers for different genes (in this case hVEGF and hIL-1Ra) and thus we 
can only compare the results relative to the house keeping genes. Also, it is known that 
there is a poor correlation between mRNA and protein levels. That is why we have to use 
house-keeping genes whenever we do real time PCR. Jansen et al., have hypothesized 
that low correlation of protein and mRNA levels are a result of post translational 
modifications.157 
 
Transduction process should not affect the normal insulin secretion capacity of 
human islets, which varies from batch to batch. Therefore, we measured insulin release in 
response to glucose challenge to assess the islet functional viability. As shown in Figure 
2-4, there was little decrease in the stimulation index when islets were transduced with 
Adv-hVEGF-hIL-1Ra at the dose of 1000 MOI per 1000 islets. These data indicate that 
transduction with Adv-hVEGF-hIL-1Ra had only minimal adverse effect on insulin 
producing β cells of the islets in response to glucose challenge.  
 
Several studies have shown little induction of inflammatory responses on islet 
apoptosis when islets are transduced with Adv vectors at low MOI, which is also true in 
our studies. Since we wash islets with PBS to remove any free viral particles prior to 
transplantation and these vectors being replication deficient, we do not expect the host to 
mount a rigorous immune response. While there will be no free viral particles with the 
transplanted islets, even direct administration of this dose of Adv vectors have been seen 
to be non-toxic. Studies of Crystal and coworkers further showed local delivery of low 
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and intermediate doses of replication deficient Adv vectors (1011 particles) well 
tolerated.158 
 
Most islet grafts are destroyed due to immune and inflammatory reaction mediated by 
proinflammatory cytokines. To mimic the in vivo situation of the cytokine mediated 
insults we incubated islets with a cocktail of IL-1β, TNF-α and INF-γ. Incubation with 
the inflammatory cytokines induced apoptosis in islets indicated by the increase in 
caspase-3 (Figure 2-5), which is a converging point of apoptosis for intrinsic and 
extrinsic pathways and caspase-6 and 7 are generated from caspase-3. However, the islets 
treated with 1000 and 2000 MOI Adv-hVEGF-hIL-1Ra and Adv-hIL-1Ra showed 
significantly lower levels of caspase-3 activity compared to the untransduced islets or the 
islets transducted with Adv-hVEGF at 1000 MOI and incubated in the cytokine cocktail, 
possibly due to hIL-1Ra gene expression (Figure 2-5). Similarly, incubation of islets with 
the cytokine cocktail significantly increased the number of red cells indicating dying or 
dead cells (Figure 2-6), which was much less for the islets transduced with Adv-hVEGF-
hIL-1Ra or Adv-hIL-1Ra, even after incubation with the cytokine cocktail. These results 
are well correlated with the literature where Adv vector encoding IL-1Ra150 as well as 
recombinant IL-1Ra159 have shown to protect islets from inflammatory cytokines. In 
contrast, there was no increase in caspase-3 after transduction of islets with Adv-hVEGF-
hIL-1Ra, Adv-hIL-1Ra or Adv-hVEGF in the absence of inflammatory cytokines, 
suggesting these Adv vectors are fairly safe at these tested doses. 
 
Effect of Adv-hVEGF-hIL-1Ra transduction on improvement in the survival and 
function of islets posttransplantation was determined in streptozotocin-induced diabetic 
NOD-SCID mice. We observed a reduction in blood glucose levels of mice transplanted 
with Adv-hVEGF-hIL-1Ra transduced islets than that observed with Adv-LacZ-
transduced or non-treated islets (Figure 2-7A). This increase correlated with the higher 
amount of serum insulin and C-peptide secreted by the islets at day 20 post-
transplantation (Figure 2-7B and C). These results indicate that hVEGF and hIL-1Ra co-
expression is likely to reduce the islet mass required to achieve normoglycemia. 
Although we did not examine the apoptosis in graft islet cells, our in vitro data clearly 
indicated transduction of Adv-hVEGF-hIL-1Ra led to significant reduction of caspase-3 
activity, which is the indicator of apoptosis.  
  
Revascularization of islet grafts after transplantation is an important process that 
influences long-term survival and function of the grafts. Endothelial cells reside within 
isolated islets and potentially participate in the revascularization process. 
Immunohistochemical staining in the islet bearing kidney sections at day 20 after 
transplantation was positive for human insulin, hVEGF and hvWF (Figure 2-8). Positive 
staining for insulin, which stains pancreatic -cells, corroborates the blood insulin data 
and confirms that islets are indeed functional after transplantation, which is in good 
agreement with the contemporary literature. hvWF is human endothelial cell marker. 
Therefore, relatively stronger positive staining for hVEGF and hvWF antigens by the 
Adv-hVEGF-hIL-1Ra transduced islet bearing kidney section groups indicates that blood 
vessel formation in the transplanted islets was relatively more efficient when islets were 
transduced with Adv-hVEGF-hIL-1Ra prior to transplantation. This indicates the 
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usefulness of this adenoviral vector in improving the survival and function of islets after 
transplantation.  
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CHAPTER 3. BIPARTITE ADENOVIRAL VECTOR ENCODING hHGF AND 
hIL-1Ra FOR IMPROVED HUMAN ISLET TRANSPLANATATON 
 
 
3.1. Introduction 
 
Type I diabetes is a chronic inflammatory autoimmune disease resulting from the loss 
of islet function, requiring life-long insulin therapy. Human islet transplantation has the 
potential to replace pancreatic endocrine function in patients with Type I diabetes 160,161 
One major drawback to this approach is the requirement of islets derived from two to 
four cadaver donors to treat a single patient with diabetes. In addition, required islet mass 
has been seen in successfully transplanted recipients compared with healthy people162 
Thus, an enormous shortage of human islets is a barrier to the use of islet transplantation 
on a larger scale. Despite recent success, islet transplantation still lags behind primarily 
because a large number of transplanted islets often do not function.143 
 
Islets have an intricate microvasculature, which is disrupted during islet isolation and 
purification process. Therefore, revascularization to the transplanted islets is essential for 
delivery of nutrients and oxygen to the inner core of islets for their survival.100,133,144,163 
Hepatocyte growth factor (HGF) is a potent mitogen for human islets and is known to 
increase the proliferation and expansion of -cells and promotes revascularization of 
islets, while maintaining physiologic glucose responsiveness after transplantation.104 
Overexpression of HGF in the -cells of transgenic mice directed by the rat insulin Type 
II promoter (RIP) has shown to increase -cell mass and proliferation, and improve islet 
function and islet transplant outcome.164 Ex vivo transduction of islets with an adenoviral 
(Adv) vector encoding HGF has been reported to improve the outcome of islet 
transplantation.165 Intravenous injection of Adv-HGF in streptozoticin (STZ)-induced 
diabetic mice have been shown to ameliorate hyperglycemia and prolong survival period 
in the diabetic mice.166 Moreover, HGF gene transfer has also been shown to increase the 
expression of three key β-cell genes, glucokinase, Glut-2 (the β-cell glucose transporter), 
and insulin.167  
 
Success of islet transplantation not only depends on islet revascularization, but also 
on its protection from apoptosis induced by hypoxia, oxidative stress and inflammatory 
cytokines released from resident macrophages and infiltrating immune cells at the 
transplantation site.147 More than 70% of islets become inactive in 7-14 days post-
transplantation.168 Among these cytokines, IL-1β plays a key role in apoptotic cell death. 
Inhibition of IL-1β receptor binding using interleukin-1 receptor antagonist (IL-1Ra) 
resulted in improved islet survival and function.149-151 HGF has also been reported to 
induce resistance to apoptosis.169 
 
Considering the favorable uses of hHGF and hIL-1Ra, in this study we constructed a 
bipartite Adv vector encoding these two genes (Adv-hHGF-hIL-1Ra) by cloning hIL-1Ra 
and hHGF under a separate cytomegalovirus (CMV) promoter. We determined 
transduction efficiency, islet function, and caspase-3 release upon incubation with 
inflammatory cytokine cocktail of TNF-α, IL-1β and IFN-γ. We then transplanted islets 
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under the kidney capsules of nonobese diabetic/severe combined immunodeficient 
(NOD-SCID) mice after transduction with Adv-hHGF-hIL-1Ra and determined the levels 
of blood glucose and serum insulin. Finally, the islet bearing kidney sections of these 
diabetic mice were stained for human insulin, hHGF and von Willebrand factor (vWH). 
 
 
3.2. Materials and Methods 
 
 
3.2.1. Materials 
 
Agarose, tris-borate-EDTA buffer, goat serum, glucose and haematoxylin solution 
were purchased from Sigma-Aldrich Co. (St. Louis, MO). Fetal bovine serum (FBS) and 
CMRL-1066 media were purchased from MediaTech Cellgros (Herndon, VA). Phosphate 
buffer solution (PBS) was purchased from GIBCO-BRL (Gaithersburg, MD). Human 
HGF and IL-1Ra ELISA kits and cytokines IL-1β, TNF-α and IFN-γ were purchased 
from R&D Systems (Minneapolis, MN). Human Insulin ELISA kits were purchased from 
Alpco Diagnostics (Windham, NH). RNA extraction kit and Caspase-Glo 3/7 assay kit 
were procured from Promega (Madison, WI). SYBR Green real time PCR master mix 
and reverse transcription reagents were purchases from Applied Biosystems (Foster City, 
CA). Sodium citrate was procured from Curtin Matheson Science Inc. (Houston, TX.)  
 
 
3.2.2. Methods 
 
The following methods were used with regards to generation of the adenoviral vector 
and testing its efficacy both in vitro and in vivo. 
 
 
3.2.3. Construction of Adv-hHGF-hIL-1Ra 
 
A bipartite Adv vector expressing hHGF and hIL-1Ra genes was constructed with the 
help of OD 260, Inc. (Boise, ID). Briefly, the hHGF cDNA was excised from pCMV-
hHGF using BamHI, and cloned into the BamHI site of pE1.2, which contains a CMV 
promoter, multiple cloning site, and bGH polyA signal. Similarly, hIL-1Ra cDNA was 
excised from pUMVC-hIL-1Ra vector using ScaI, separated by gel fractionation, and 
purified using Promega PCR and cleanup kit (Promega, Madison, WI). The hIL-1Ra 
fragment along with rabbit β-globin polyA was then cloned into pE3.1 shuttle plasmid 
using NotI restriction site. The pE 3.1 IL-1Ra plasmid was further modified by removing 
the intron adjoining CMV promoter. All the ligation reactions were done at 1:3 and 1:10 
ratios using T4 DNA ligase and then transformed in super competent TOP 10 cells and 
amplified in terrific broth media. The plasmids were then purified using Gen Elute 
plasmid Mini prep kit (Sigma-Aldrich, St. Louis, MO). The plasmids pE 1.2-hHGF and 
pE 3.1-hIL-1Ra were digested with AlwNI and DraIII respectively and the excised 
fragments were purified on agarose gel. These fragments were ligated with SfiI-digested 
AdenoQuick 13.1 plasmid simultaneously using T4 DNA ligase overnight at 16ºC. The 
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ligated products were packaged into phage lambda particles using MaxPlax packaging 
extract (Epicentre, Madison, WI). The packaging mixture was used to infect E. coli XL-
1Blue (Stratagene) and clones were selected on LB supplemented with 25µg/ml 
kanamycin and 50µg/ml ampicillin. The Pac I linearized cosmid was transfected into 293 
cells to rescue the virus. Three viral plaques were amplified, and their genomic DNAs 
were extracted. The presence of hHGF and hIL-1Ra expression cassettes in these three 
vectors was confirmed by restriction analysis with SpeI and EcoRV, respectively. The 
clone containing the two genes was infected to 293 cells. Both the cells and the medium 
were harvested and frozen/thawed three times. This viral extract was further infected into 
293 cells, amplified and purified on two CsCl gradients. The bands harvested were 
dialyzed against 3X1 l GTS buffer (25% glycerol, 25mM NaCl, 20mM Tris-HCl (pH 8) 
for 12 hours at 4ºC. The dialyzed viral suspension was collected, filtered and stored at  
-70ºC. 
 
 
3.2.4. Determination of Viral Titer 
 
The infectious viral titer was also determined by using an Adeno-X rapid titer kit 
from Clontech (Mountain View, CA). Different dilutions of Adv-HGF-hIL-1Ra was 
taken and transduced to AD-293 cells, using un-transduced cells as a control. After 48h 
post-transduction, AD-293 cells were fixed and incubated with Anti-Hexon antibody, 
followed by a secondary horse radish peroxidase (HRP)-conjugated antibody. Then the 
cells were stained with 3, 3’ diaminobenzidine tetrahydrochloride (DAB) substrate and 
positively stained cells were counted under a microscope, and the titer was determined.  
 
 
3.2.5. Islet Culture and Transduction 
 
Human Islets were received from one of the several Islet Cell Resource (ICR) Centers 
in culture media at 4°C. Upon receipt, the islets were cultured in CMRL-1066 medium 
containing 10% fetal bovine serum (FBS) and 1% Penicillin Streptomycin. Islets were 
then transduced with Adv hHGF-hIL-1Ra, while non-transduced islets were used as 
controls. To determine the optimal multiplicity of Infection (MOI) of Adv in terms of 
plaque forming units (pfu) per islet equivalent, 1000 islets were incubated with diluted 
adenovirus at 100, 500, 1000, 2000 and 5000 MOI in 300μl media in a 96 well plate for 
12h, followed by washing and further culture in 1ml of media in 24-well plates. Gene 
expression was determined at days 1 and 3 by quantifying secreted protein in the media 
by ELISA (R&D Systems, Minneapolis, MN). Total protein of the islet cell extracts was 
also determined using the bicinchoninic acid (BCA) protein assay kit to normalize the 
results. Three samples per group were included for the experiment.  
 
 
3.2.6. Quantitative Real Time PCR  
 
To determine hHGF and hIL-1Ra gene expression in human islets at the mRNA level 
by real time RT-PCR, at day 3 post-transduction of islets with Adv-hHGF-hIL-1Ra the 
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islet pellet was collected for isolation of total RNA using RNAeasy mini isolation kit 
from Promega. RNA concentration was measured by UV spectrophotometry using 
Biomate 3 spectrophotometer. Two hundred and fifty nanograms (ng) of extracted RNA 
was converted into cDNA using MultiScribe reverse transcriptase and random hexamers 
(Applied Biosystems, Inc., Foster City, CA) by incubation at 25°C for 10 min, followed 
by reverse transcription at 48°C for 30 min and enzyme inactivation at 95°C for 5 min. In 
all 3.85μl of cDNA was amplified by real time RT-PCR. To determine the level of HGF 
expression, the following hHGF-specific primers were used: Forward: 5'-CCT ATG CAG 
AGG GAC AAA GGA A-3'; Reverse: 5'-GCC TTG CAA GTG AAT GGA AGT CCT-3' 
(NCBI Accession#291674). In case of hIL-1Ra both, forward (5’-ATC CAG CAA GAT 
GCA AGC CCT-3’) and reverse (5’-TTC GTC AGG CAT ATT GGT GAG GCT-3’) 
primers were designed from the gene sequence, (NCBI Accession#AK290898). The PCR 
conditions included denaturation at 95°C for 10 min, followed by 40 cycles of 
amplification by sequential denaturation at 95°C for 15 sec and primer annealing as well 
as strand extension for 1 min. hHGF and hIL-1Ra gene expression was normalized to 19s 
rRNA as internal control. 
 
To confirm the amplification specificity, the PCR products were subjected to melting 
curve analysis. The expressed HGF and hIL-1Ra levels were quantified and normalized 
to the total amount of cDNA used. Threshold cycle number was compared between Adv-
hHGF-hIL-1Ra with the same parameters using non-transfected islets as controls. 
 
 
3.2.7. In Vitro Islet Function after Infection 
 
The in vitro function of human islets after infection with Adv-hHGF-hIL-1Ra was 
determined by the static incubation method. Non-infected islets were used as control. 
Transfected media was removed by centrifugation at 300g and the islets were 
sequentially incubated at 37ºC for 1h in the media containing 2.5mM (basal) and 22mM 
glucose (stimulated). After incubation, supernatants were collected and analyzed for 
insulin release by ELISA (Alpco Diagnostics). Insulin secretion was expressed as µU/ml 
and the ratio of insulin levels at 22mM to 2.5mM glucose was used to calculate the 
stimulation index.  
 
 
3.2.8. Cytoprotective Effect of Adv-hHGF-IL-1Ra  
 
One thousand islets per well of 96 well plates were infected with 1000 MOI of Adv-
HGF-hIL-1Ra at 500, 1000 and 2000 MOIs. At 12h post-transduction, islets were washed 
and incubated with a cocktail of IL-1β (10ng/ml), TNF-α (10ng/ml) and IFN-γ (50ng/ml) 
cytokines. Non-transduced islets with and without cytokine treatment were used as 
controls. Blank media was also used the negative control. At day 3 post transduction 
islets were collected from each well and were lysed with lysis buffer to measure the 
caspase-3 concentration using the Caspase-Glo 3/7 Assay kit (Madison, WI). 
 
 
50 
3.2.9. Western Blotting 
 
At day 3 post-transduction of human islets with Adv-hHGF-hIL-1Ra, protein extracts  
were prepared by washing cells with PBS and lysing in RIPA buffer containing protease 
inhibitor (Roche, Basel, Switzerland). Human islets were homogenized and lysates were 
spun at 15000g for 15 min to remove insoluble material. Protein concentrations were 
determined by BCA protein assay. Proteins were resolved on 4-15% sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Bio-Rad, Hercules, CA) and 
transferred to a PVDP membrane (Bio-Rad, Hercules, CA), blocked with TBST buffer 
composed of 50mM Tris (pH 7.6), 150mM NaCl and 0.05% Tween supplemented with 
5% fat-free milk at 4C for 1h. After a brief rinse, the membrane was incubated overnight 
at 4°C in TBST containing 0.5% milk with mouse anti-human Bcl-2 (Santa Cruz, CA) 
(1:200) and mouse anti-human Bax (Santa Cruz, CA). Goat anti-human Actin 
monoclonal antibody (Santa Cruz, CA) (1:2000) was used for detecting an internal 
control protein. Then, blots was washed four times using TBST for 1h at room 
temperature. Immunodetection was performed using a horseradish peroxidase (HRP) 
Chemi Blot Starter Kit (Bio-rad, Hercules, CA) according to the manufacture’s 
instruction.  
 
 
3.2.10. Islet Transplantation Studies 
 
Animal experiments were performed as per the NIH 
(http://grants1.nih.gov/grants/olaw/ references/phspol.htm) and institutional animal care 
and use guidelines using the approved protocol. To induce diabetic animal model, 
streptozotocin (STZ) (40mg/kg) was administered to NOD-SCID mice by intraperitoneal 
injection for 5 consecutive days. Animals were considered to be diabetic after two 
consecutive measurements of blood glucose≥300mg/dl using a One Touch Ultra 
Glucometer (LifeScan, Inc.). Before transplantation, human islets were transduced by 
Adv-hHGF-hIL-1Ra at the dose of 1000 MOI for 12h and washed with PBS. About 1000 
transduced or non-treated islets were transplanted under the left kidney capsules of 
diabetic mice. The nonfasted glucose levels were measured from the snipped tail of each 
animal up to 28 days post-transplantation. At day 28 post-transplantation, the mice were 
then anesthetized to collect blood to measure serum insulin and c-peptide levels by 
ELISA (Alpco Diagnostics, Salem, NH). At day 28, the graft-bearing kidneys were 
removed from some animals to confirm the function of islet grafts by the return of blood 
glucose levels to300mg/dL for two consecutive days. 
 
 
3.2.11. Intraperitoneal Glucose Tolerance Test 
 
Twenty seven days after islet transplantation under the kidney capsules of STZ- 
induced NOD-SCID diabetic mice, glucose tolerance was analyzed in overnight fasted 
mice by intraperitoneal injection of 2g of glucose/kg of body weight as described by 
Garcia-Ocana et al.165 Blood samples were obtained from the snipped tail and analyzed 
for glucose levels using a One Touch Ultra Glucometer (LifeScan, Inc.). 
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3.2.12. Immunohistochemistry and Morphometric Analysis 
 
To determine hHGF expression and angiogenesis, transplanted mice were sacrificed, 
kidneys were isolated, washed with PBS, fixed in 4% formaldehyde overnight, and 
embedded in paraffin as described before.133 Sections of 5-7µm thickness were cut and 
immunostained with rabbit anti-insulin, hHGF and hvW primary antibodies, respectively. 
The immunoreactivity was detected using goat anti-rabbit IgG, H&L chain specific 
peroxidase conjugate and subsequent incubation with DAB substrate. For morphometric 
analysis, hHGF and hvWF-positively immunostained color (brown in each case) was 
selected for quantification of the relative intensity using NIH Image 1.62 software to 
determine the mean values, which were subsequently compared between Adv-hHGF-hIL-
1Ra transduced and control islet transplanted diabetic recipient mice. 
 
 
3.2.13. Statistical Analysis 
 
Statistical significance of the difference between the two groups was determined by 
unpaired t-test and between several groups by one-way ANOVA. 
 
 
3.3. Results 
 
The results obtained from these studies are outlined below. 
 
 
3.3.1. Construction of Adv-hHGF-hIL-1Ra 
 
Adv-hHGF-hIL-1Ra is a serotype 5 based replication deficient Adv vector that 
contains a CMV promoter, hHGF cDNA and rabbit β-globin poly A in the E-1 region and 
a CMV promoter, hIL-1Ra cDNA and rabbit β-globin poly A in the E-3 region (Figure  
3-1). hHGF and hIL-1Ra coding sequences and polyA signals were placed under the 
control of a separate CMV promoter cloned into pE1.2 and pE3.1. The resulting vectors 
were combined in Adenoquick 13.1 to generate a cosmid that contains the entire 
sequence of recombinant adenovirus. The presence of hHGF and hIL-1Ra expression 
cassettes in these vectors was confirmed by restriction digestion with Hind III (data not 
shown). The number of viral particles in the stock solution of Adv-hHGF-hIL-1Ra was 
determined using an Adeno X rapid titer kit from Clontech (Mountain View, CA) and the 
titer was calculated to be 1.24X10^9 ifu/ml (infectious units/ml). 
 
 
3.3.2. Transduction Efficiency of Adv-hHGF-hIL-1Ra 
 
Following the transduction of human islets with Adv-hHGF-hIL-1Ra, the level and 
duration of hHGF and hIL-1Ra proteins increased with increase in MOI. hHGF and hIL-
1Ra protein levels at day 3 post-transduction was over 60 and 40 times higher than that of 
the untransduced islets, respectively (Figure 3-2), indicating that Adv-hHGF-hIL-1Ra 
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Figure 3-1 Construction of E1 and E3 deleted bipartite Adv-hHGF-hIL-1Ra.  
 
Adv-HGF-hIL-1Ra was constructed by excising hHGF and hIL-1Ra form vector 
pUMVC and cloning into the multiple cloning sites of shuttle plasmids pE 3.1 and pE 1.2 
using NotI. The expression cassettes of hHGF and hIL-1Ra containing the CMV 
promoter were cloned into AdenoQuick plasmid 13.1 to generate a cosmid containing the 
entire sequence of recombinant adenovirus. After transfection into 293 cells, recombinant 
adenovirus Adv-hHGF–hIL-1Ra was produced. 
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Figure 3-2 Expression of HGF and IL-1Ra genes at protein level. 
 
Time profile of hHGF and hIL-1Ra gene expression at protein levels in human islets 
transduced Adv-HGF-IL-1Ra at different multiplicities of transduction (MOI) 100, 500, 
1000, 2000 and 5000 per 1000 islets. Non-transduced islets were used as controls. ELISA 
of cell culture supernatants were performed at days 1 and 3. Cumulative expression levels 
were presented as the mean±S.D. (n=4). N, non-transduced control islets. Difference 
between any two groups was determined by ANOVA. P<0.05 was considered statistically 
significant. 
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transduction would lead to high local concentrations of hHGF and hIL-1Ra in the  
immediate vicinity of islets post transplantation. We also determined hHGF and hIL-1Ra 
gene expression at mRNA levels by real time RT-PCR. As shown in Figure 3-3, the 
normalized mRNA concentration to that of the control was significantly increased with 
increase in MOI of Adv-hHGF-hIL-1Ra. Gene expression at mRNA level of hHGF and 
hIL-1Ra was more than 60 and 40 times higher than that of untransduced islets, 
respectively (Figure 3-3). Each graph is indicative of the relative increase in expression 
of hHGF and hIL-1Ra independently. This shows that Adv-hHGF-hIL-1Ra can 
simultaneously express both genes with high efficiency. The mRNA concentrations of 
each gene were normalized to that of the control i.e., untransduced islets. The 
amplification specificity was confirmed by melting peak analysis, which showed a single 
predominant peak each for s19 (84.5°C), hHGF (78.8°C) and hIL-1Ra (85.5°C), 
respectively (data not shown). 
 
 
3.3.3. Effect of Viral Transduction on Islet Function 
 
To determine whether insulin secretion was adversely affected by transduction of 
islets with Adv-hHGF-hIL-1Ra, insulin secretion in response to glucose challenge was 
carried out at day 3 post-transduction at 500, 1000 and 2000 MOI, while non-transduced 
islets were used as the control. Glucose challenge was determined by quantifying glucose 
stimulated insulin release at basal level (2.5mM) and stimulated (22mM) glucose 
concentrations. There is a significant decrease in the stimulation index of un-transduced 
control islets when incubated with the cytokine cocktail compared to that in the absence 
of cytokine incubation (Figure 3-4). 
 
Stimulation indices of Adv-hHGF-hIL-1Ra-transduced islets were almost identical to 
that of untransduced islets, when they were not incubated with the cytokine cocktail, 
suggesting that the transduction process does not cause any harm to the islets. Although 
incubation with the cytokine cocktail also led to decrease in the stimulation indices of 
Adv-hHGF-hIL-1Ra transduced islets, this decrease was much less compared to that of 
the un-transduced control islets, possibly due to the protective effect of hHGF and hIL-
1Ra co-expression (Figure 3-4). 
 
 
3.3.4. Apoptosis of Islets 
 
Apoptosis of islets leads to their impaired function and subsequent death, and thus it 
is an important detriment to islet transplantation. Caspase-3 is the converging point of 
apoptotic pathways. Therefore, we determined the level of caspase-3 in the islets 
transduced with Adv-hHGF-hIL-1Ra, following by incubation with the cytokine cocktail 
of IL-1β, TNF-α and IFN-γ. Non-transduced control islets with and without cytokine 
treatment were used as controls. As shown in Figure 3-5, caspase-3 activity was high in 
the un-transduced islets treated with the cytokine cocktail compared to that in the absence 
of the cytokine cocktail. Transduction of islets with Adv-hHGF-hIL-1Ra protected islets 
from cytokine induced apoptosis as evidenced by low increase in caspase-3 levels  
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Figure 3-3 Real time PCR of Adv-hHGF-hIL-1Ra transduced human islets. 
 
Real time PCR of human islets at day 3 post transduction with Adv-HGF-IL-1Ra at 
different MOI of 100, 500, 1000, 2000 and 5000. Forward and reverse primers were 
designed from hIL-1Ra and HGF genes. Non-transduced islets were used as controls. 
Cell pellet was collected at day 3 and processed for mRNA extraction, reverse 
transcription and real time PCR using SYBR green chemistry. The normalized mRNA 
values of the different MOI treated islets are plotted. Since different primers were used, 
no direct comparison can be made, other than demonstration of increase in mRNA levels 
with increase in MOI. N, non-transduced control islets. Difference between any two 
groups was determined by ANOVA. P<0.05 was considered statistically significant. 
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Figure 3-4 Glucose Stimulation Index. 
 
Stimulation index (SI) of human islets with or without cytokine incubation after 
transduction with Adv-hHGF-IL-1Ra at 500, 1000 and 2000 MOI. Non-transduced islets 
were used as controls. SI was determined as the ratio of insulin release from islets when 
they are incubated at 396mg/dl and 45mg/dl glucose containing media. Increase in insulin 
secretion in response to high glucose concentration and decrease with reducing 
concentration is significant of metabolically healthy and functional islets. Results are 
expressed as a mean±S.D of n=4. 
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Figure 3-5 Effect of hHGF and hIL-1Ra co-expression on caspase-3 activity. 
 
Following transduction with Adv-hHGF-hIlL-1Ra, islets were incubated with a 
cocktail of cytokines, such as IL-1β (10ng/ml), TNF-α (10ng/ml) and INF-γ (50ng/ml). 
Non-transduced islets with and without cytokine treatment were used as controls. Blank 
media was also used as negative controls. Caspase-3 activity was determined at day 3 
post-transduction by measuring the amount of caspase-3 present in the lysate of islets 
after cell lysis using a Caspase-Glo 3/7 luciferase assay. Results are expressed as the 
mean±S.D. of n=4. *p<0.05 and **p<0.02, compared to non-transduced islets with 
cytokine treatment. NT, non-transduced islets without cytokine treatment. 
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compared to that of non-traduced islets incubated with the cytokines. Since the islets 
transduced at 2000 MOI showed much higher level of caspase-3 activity compared to that 
of 1000 MOI transduced islets, we decided to transduce islets at 1000 MOI for in vivo 
testing. The inability of Ad5 vectors to be integrated into the host genome is another 
attribute of the Ad5 vectors that make them an attractive vector for transgene expression. 
Also the Ad5 vectors lacking the E1 and E3 genes render them to produce less immune 
response.170-172 The viral proteins synthesized will be minimal. However, a major concern 
in the use of adenoviral vectors is safety. Therefore, the vector associated immune 
response will be minimal. This is a very significant factor that needs to be thoroughly 
addressed before it can be used in a clinical setting. Although the adenoviral vectors are 
replication deficient, there are reports in the literature suggesting the immune response 
these vectors could elicit following their administration.85,172,173 We have seen that at 
higher doses 2000 MOI there was increase in caspase-3 activity in the islets transduced 
by the Adv indicating that higher doses of the Adv can be detrimental to the survival of 
islets following transplantation. This might be due to increase in vector backbone 
resulting in eliciting immune response. Also, the viral proteins can elicit an immune 
response. Therefore, we decided to use 1000 MOI of Adv concentration in all the studies. 
We also determined the effect of Adv-hHGF-hIL-1Ra transduction on the levels of Bcl-2 
(anti-apoptotic) and Bax (pro-apoptotic) by Western blot analysis. As shown in Figure  
3-6, there was significant increase in Bcl-2 level, but decrease in Bax level. 
 
 
3.3.5. Islet Survival and Function after Transplantation 
 
The effect of hHGF and hIL-1Ra gene expression on the islet survival and function 
post-transplantation of 1000 islets transduced with Adv-hHGF-hIL-1Ra at 1000 MOI 
under the kidney capsules of NOD-SCID mice was determined in terms of blood glucose, 
human insulin, and C-peptide levels. Following transplantation, blood glucose level 
decreased to around 200mg/dl for both the un-transduced control and Adv-hHGF- hIL-
1Ra-transduced islet transplanted mice. However, the mice transplanted with un-
transduced islets showed gradual increase in the blood glucose level reaching to 
300mg/dl at day 28 post-transplantation. In contrast, no increase blood glucose level was 
seen in case of the mice transplanted with Adv-hHGF-hIL-1Ra-transduced islets even at 
28 day post-transplantation (Figure 3-7). After removal of the kidney containing islets 
from some mice, blood glucose levels immediately returned to pre-transplant diabetic 
levels (>500mg/dL), confirming that the transplant was responsible for reducing the 
blood glucose (Figure 3-7).To further define the function of the transplanted islets, 
glucose tolerance tests were performed at day 27 post-transplantation from the same 
mice. 
 
After intraperitoneal glucose injection, blood glucose values were significantly lower 
in mice transplanted with Adv-hHGF-hIL-1Ra-transduced islets than in mice transplanted 
with uninfected islets (Figure 3-8). These results collectively indicate that at 4 weeks 
after transplantation of an equivalent mass of islets, Adv-hHGF-hIL-1Ra-transduced 
islets lead to superior glucose control and to tolerance as compared with control islets. 
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Figure 3-6 Effect of Adv-hHGF-hIL-1Ra on Bcl-2 and Bax protein levels. 
 
Following transduction with Adv-hHGF-hIlL-1Ra, islets were incubated with a 
cocktail of cytokines, such as IL-1β (10ng/ml), TNF-α (10ng/ml) and INF-γ (50ng/ml). 
Non-transduced islets with and without cytokine treatment were used as controls. Bcl-2 
and Bax was determined at day 3 post-transduction by Western blot analysis. Lane 1, 
non-transduced islets; lane 2, non-transduced islets with cytokine treatment; lane 3, islets 
transduced with Adv-hHGF-hIL-1Ra at 500 MOI with cytokine treatment; and lane 4, 
islets transduced with Adv-hHGF-hIL-1Ra at 1000 MOI with cytokine treatment.  
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Figure 3-7 Transplantation of Adv-hHGF-hIL-1Ra transduced islets. 
 
Following transduction with Adv-hHGF-hIL-1Ra at 1000 MOI, 1000 islets were 
transplanted under the kidney capsule of streptozotocin-induced diabetic NOD-SCID 
mice. The mice transplanted with un-transduced islets were used as controls. The 
nonfasting glucose levels were measured in each animal up to 28 days post-
transplantation using a One Touch Ultra Glucometer (LifeScan, Inc.). 
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Figure 3-8 Intraperitoneal Glucose Tolerance Test. 
 
Glucose tolerance in streptozotocin-induced NOD-SCID mice transplanted with 
uninfected or Adv-hHGF-hIL-1Ra transduced islets. At day 27 after the transplant, mice 
were fasted overnight and then injected intraperitoneally with glucose (2g/kg of body 
weight). Blood glucose levels were measured from the snipped tail at the time points 
indicated with a glucometer. Results are the mean±S.D. of n=4. *P<0.05 compared with 
control using ANOVA. 
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Just before the removal of kidney containing islets, blood was collected for measuring 
the serum insulin and C-peptide levels. As shown in Figure 3-9A and B, serum levels of 
insulin and c-peptide were significantly higher in mice transplanted with Adv-hHGF-hIL-
1Ra transduced islets compared to un-transduced islet transplanted mouse groups, 
indicating better islet engraftment and function. These results suggest that compared to 
non-treated islets, co-expression of hHGF and hIL-1Ra sustained the low glucose level of 
mice for prolonged period, and increased the levels of serum insulin and c-peptide.  
 
 
3.3.6. Immunohistochemistry  
 
To determine whether hHGF gene expression after transduction with Adv-hVEGF-
hIL-1Ra will promote angiogenesis by human islets, we isolated the kidney bearing Adv-
hHGF-hIL-1Ra transduced islets at 28 days post-transplantation into diabetic NOD-SCID 
mice for sectioning and staining with polyclonal rabbit hHGF and von Willebrand Factor 
(hvWF) antibodies. Staining with anti-human insulin and untransduced islet sections 
were used as the controls. The positive staining of hHGF was higher in the transduced 
islets compared to un-transduced islets (Figure 3-10), suggesting efficient hHGF gene 
expression after transduction with Adv-hHGF-hIL-1Ra. The positive staining of vWF 
factor was more evident in Adv-hHGF-hIL-1Ra transduced islets, which is an indicator 
for endothelial cells. Morphometric analysis revealed that Adv-hHGF-hIL-1Ra 
transduced islet grafts exhibited higher hHGF and vWF-immunostaining intensity than 
control islet grafts, with relative intensities of 1.70 vs. 1 for hHGF and 1.50 vs. 1 for 
hvWF respectively. 
 
To correlate the degree of islet revascularization with the islet mass in the kidney 
capsule, we also stained for human insulin. Adv-hHGF-hIL-1Ra transduced islets (Figure 
3-10A) displayed significantly higher levels of insulin content than control islet groups 
(Figure 3-10D), with relative intensity of 1.7 vs. 1. This quantitative difference in insulin 
content in the kidney capsule between Adv-hHGF-hIL-1Ra transduced and control islet 
groups of diabetic recipient mice correlated well with their serum insulin and c-peptide 
profiles (Figure 3-9). The positive staining for human insulin also confirmed the 
functionality of islets. These results indicate the beneficial effect of Adv-hHGF-hIL-1Ra 
for the islet survival and function post-transplantation. 
 
 
3.4. Discussion 
 
Isolation and purification of islets are known to disrupt their microvasculature, 
leading to hypoxia and apoptosis upon transplantation.133 HGF has been shown to 
increase -cell proliferation vitro and ameliorate hyperglycemia in streptozotocin-
induced diabetic mice transplanted with murine islet transplantation.164,165,174 
 
Islet injury stimulates resident macrophages and infiltrating leukocytes to produce 
cytotoxic cytokines like IL-1β, TNF-α and IFN-γ. Among these inflammatory cytokines, 
IL-1β is the key mediator of β cell destruction. Administration of recombinant IL-1Ra  
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Figure 3-9 Serum insulin and c-peptide ELISA. 
 
Following ex vivo transduction with Adv-hHGF-hIL-1Ra at 1000 MOI, 1000 islets 
were transplanted under the kidney capsule of streptozotocin-induced diabetic NOD-
SCID mice. The mice transplanted with un-transduced islets were used as controls. At 
day 28 post-transplantation, the mice were sacrificed and blood was collected to measure 
A) serum insulin and B) C-peptide by ELISA. Results are expressed as the mean±S.D. 
(n=4) *p<0.05. 
A B 
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Figure 3-10 Immunohistochemical staining of islet bearing kidney sections. 
 
Immunohistochemical staining of islet bearing kidney sections at 28 days post-
transplantation of human islets transduced with Adv-hHGF-hIL-1Ra at 1000 MOI. 
Rabbit polyclonal anti-human HGF and hvW were used for detecting hHGF and 
endothelial cells. A) Insulin, B) hvW and C) hHGF staining for Adv-hHGF-hIL-1Ra-
transduced islets; and D) insulin, E) hvW and F) hHGF staining for the control islets.  
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protein has been shown to prevent islet dysfunction upon transplantation.151 Ex vivo 
transduction of human islets with Adv-hIL-1Ra has been reported to prevent IL-1β 
induced β cell impairment and activation of islet cell apoptosis.150 On the other hand, 
HGF is known to induce angiogenesis, regenerate β-cells and protect islets from 
apoptosis. Therefore, the objective of this study was to construct and characterize a 
bipartite Adv vector, Adv-hHGF-hIL-1Ra, for enhancing the performance of human islet 
grafts and correction of hyperglycemia upon transplantation under the kidney capsules of 
STZ-induced diabetic NOD-SCID mice. 
 
Apoptosis begins during the islet isolation process, peaks 2-3 days post 
transplantation, and continues for approximately 7~14 days until what remains of the 
graft has stabilized and become vascularized. Therefore, the use of replication deficient 
Adv vectors promotes islet engraftment during the first week may be all that is necessary. 
The lack of integration is an advantage as well, since it will not allow induction of several 
key cell genes. The viral dose delivered to the patient by ex vivo gene therapy would be 
small reducing concerns regarding anaphylaxis. Finally, hHGF and hIL-1Ra co-
expression will suppress immune reaction, leading to attenuation of host allergic 
reactions. Therefore, we decided to use ∆E1 and ∆E3 Adv vector because our goal was to 
achieve transient gene expression, while avoiding other potential side effects and in vivo 
virus replication. Since prolonged incubation with Adv vectors may induce apoptosis and 
loss of endothelial cells; we decided not to co-culture the islets beyond 12h, we 
determined HGF and hIL-1Ra gene expression at protein and mRNA levels. The protein 
and mRNA levels of HGF and hIL-1Ra increased with increase in MOI (Figures 3-2 and 
3-3), indicating the Adv vector is indeed expressing these two genes as desired. However, 
these results cannot be directly correlated, since we used different primers for different 
genes and thus we can only compare our real time RT-PCR results in relative to the house 
keeping genes. 
 
Apoptosis is a major pathway through which islets undergo cell death and has been 
considered as a major factor for primary graft non-function.175 To mimic the in vivo 
situation of the cytokine mediated insults, we incubated islets with a cocktail of 
inflammatory cytokines such as IL-1β, TNF-α and IFN-γ. Caspase-3 is a converging 
point of apoptosis for intrinsic and extrinsic pathways and caspase-6 and 7 are generated 
from caspase-3. There was gradual increase in caspase-3 with increase in Adv-hHGF-
hIL-1Ra in the presence of these cytokines, but caspase-3 levels were much lower 
compared to the un-transduced islets (Figure 3-5). The levels of caspase-3 at 500 and 
1000 MOI was low, suggesting these Adv vectors are fairly safe at these tested doses. 
Bcl-2 family of intracellular proteins plays an important role in regulation of cytochrome 
C release into the cytosol and caspase activation. Anti-apoptotic members, such as Bcl-2, 
Bcl-XL and Bcl-w are critical for cell survival, whereas pro-apoptotic members, such as 
Bax, Bad and Bak among others promote apoptosis.176 Heterodimerization of Bcl-2 with 
Bax or Bak modulates apoptosis, and the ratio of Bcl-2 to Bax or Bak determines survival 
or death following an apoptotic stimulus. Transduction of islets with Adv-hHGF-hIL-1Ra 
greatly enhanced the level of Bcl-2 protein while inhibited Bax protein level (Figure 3-6). 
This result further demonstrates the protective effect of hHGF and hIL-1Ra co-expression 
since Bcl-2 has been shown to inhibit cytochrome C release and protect against oxidative 
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stress-induced apoptosis,177 indicating the usefulness of this vector in protecting islets 
from apoptosis following transplantation.  
 
Effect of Adv-hHGF-hIL-1Ra transduction on improvement in the survival and 
function of islets post-transplantation was determined in streptozotocin-induced diabetic 
NOD-SCID mice. We observed a reduction in blood glucose levels of mice transplanted 
with Adv-HGF-hIL-1Ra transduced islets than that observed with un-transduced islets, 
especially after 5 days post-transplantation, but increase in blood glucose levels for the 
mice transplanted with un-transduced islets (Figure 3-6). This decrease in blood glucose 
levels by Adv-hHGF-hIL-1Ra-transduced mice correlated with the higher amount of 
serum insulin and C-peptide secreted by the islets at day 28 post-transplantation (Figure 
3-9A and B). Our results are in good agreement with Lopez-Talavera et al.,146 who 
observed glycemic control in Adv-HGF-transduced islet transplanted rats superior to the 
tat observed in diabetic control rats. Revascularization of islet grafts after transplantation 
is an important process that influences the long-term survival and function of the grafts. 
Endothelial cells reside within isolated islets and potentially participate in the 
revascularization process. Immunohistochemical staining in the islet bearing kidney 
sections at day 28 after transplantation was positive for human insulin, hHGF and vWF 
(Figure 3-10). Positive staining for insulin, which stains pancreatic β-cells corroborates 
the serum insulin data (Figure 3-9A) and confirms that islets are indeed functional after 
transplantation, which is in good agreement with the contemporary literature. vWF is 
human endothelial cell marker. Therefore, relatively stronger positive staining for hHGF 
and vWF antigens by the Adv-hHGF-hIL-1Ra transduced islet bearing kidney section 
groups indicates that blood vessel formation in the transplanted islets was relatively more 
efficient when islets were transduced with Adv-hHGF-hIL-1Ra prior to transplantation. 
 
These results indicate that HGF and hIL-1Ra co-expression is likely to reduce the 
islet mass required to achieve normoglycemia. Although we did not examine the 
apoptosis in graft islet cells, our in vitro data clearly indicated that transduction of Adv-
HGF-hIL-1Ra led to significant reduction of caspase-3 activity, which is the indicator of 
apoptosis. 
 
We have tested two different adenoviral vectors Adv-hVEGF-hIL-1Ra and Adv-
hHGF-hIL-1Ra by transducing them into human islets and studying their survival and 
function following transplantation in NOD-SCID mice. Both VEGF and HGF are 
angiogenic growth factors. However, we replaced VEGF with HGF as HGF not only 
promotes revascularization, but also can protect the islets from apoptosis. It can also 
promote the proliferation of β-cells and also has shown to decrease the islet mass needed 
for achieving normoglycemia. In our studies, we have seen that the islets transduced with 
Adv-hHGF-hIL-1Ra maintained normoglycemia in diabetic NOD-SCID mice for longer 
period compared to islets transduced with Adv-hVEGF-hIL-1Ra. Also, we have seen the 
toxicity of adenoviral vectors at higher doses thereby needing to decrease the viral dose 
for transducing islets prior to transplantation. Considering all these factors, it can be 
clearly said that Adv-hHGF-hIL-1Ra is more apt for transducing the human islets to 
improve their survival and function following transplantation. Although, further studies 
are warranted to study the immunogenicity of the adenoviral vectors, their effect 
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following transplantation of Adv transduced islets in the hepatic portal vein mimicking 
the human setting to clearly say about the usefulness of these vectors in clinical setting. 
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CHAPTER 4. TRIPLEX FORMING OLIGONUCLEOTIDES AGAINST TYPE 
ΑLPHA 1(I) COLLAGEN ATTENUATES LIVER FIBROSIS INDUCED BY BILE 
DUCT LIGATION 
 
 
4.1. Introduction 
 
Liver fibrosis results from chronic damage to the liver in conjunction with the 
accumulation of extracellular matrix (ECM) proteins, which is a characteristic of most 
chronic liver diseases.68 The main causes of liver fibrosis in industrialized countries 
include chronic hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic 
steatohepatitis (NASH). Such chronic diseases lead to scarring in the liver that, with 
increasing severity, prevents effective liver regeneration and maintenance of liver 
function.178 Liver fibrosis is associated with major alterations in both the quantity and 
composition of ECM. The accumulation of ECM proteins distorts the hepatic architecture 
by forming a fibrous scar, and the subsequent development of nodules of regenerating 
hepatocytes defines cirrhosis.179  
 
Type I collagen, the major component of the extracellular matrix in the fibrotic liver, 
is a heterotrimer composed of 2 1 chains and 1 2 chain. These chains are encoded by 2 
distinct genes, COLlAl and COLlA2, respectively. Hepatic stellate cells (HSCs; also 
known as vitamin A-storing cells, fat-storing cells, Ito cells, and lipocytes) residing in the 
perisinusoidal space of Disse in the liver, are the main producers of type α1(I) collagen 
and other components of extracellular matrix in both normal and fibrotic livers.180,181 
Following chronic injury, cytokines such as transforming growth factor β (TGF-) and 
protein kinase signaling pathways mediate a complex interplay among different hepatic 
cells.182-184 Under the influence of these signals, HSCs activate or transdifferentiate into 
myofibroblast-like cells, acquiring contractile, proinflammatory, and fibrogenic 
properties resulting in increased synthesis of types I and III fibrillar collagen.185,186  
 
In contrast to the traditional view that cirrhosis is an irreversible disease, recent 
evidence indicates that even advanced fibrosis is reversible.187,188 Preclinical studies have 
reported a scientific rationale and experimental evidence supporting the use of many 
potential therapies for fibrosis. Such therapies have been targeted to any of several 
different biological targets (e.g., inhibition of collagen synthesis, interruption of matrix 
deposition, stimulation of matrix degradation, modulation of stellate cell activation, or 
induction of HSC death). Triplex-forming oligonucleotides (TFOs) constitute an 
interesting DNA sequence-specific tool that can be used to target cleaving or cross-
linking agents, transcription factors or nucleases to a chosen site on the DNA. TFOs have 
proved effective in altering gene expression by interfering with the binding of 
transcription factors.189,190 Because liver fibrosis is due to the overproduction of Type I 
collagen by liver fibrogenic cells, targeted inhibition of transcription of type α1(I) 
collagen gene is expected to prevent fibrosis. Recently, we showed that antiparallel 
phosphorothioate (APS) TFOs specific for α1(1) collagen form triplexes efficiently and 
inhibit transcription in cultured immortalized rat hepatic stellate cells (HSC-T6) in 
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vitro.191 These results suggest that targeting collagen transcription may theoretically 
attenuate fibrosis in livers undergoing tissue remodeling. 
 
In the current study, we studied the antifibrotic effects of TFOs in rats undergoing 
common bile duct ligation (CBDL). TFO administration in CBDL rats resulted in 
decreased liver injury, inflammation, and fibrosis. At the cellular level, TFO induced 
similar effects in primary rat HSCs. This evidence indicates that the prevention of fibrosis 
by anti-collagen TFO treatment could preserve organ function and be therapeutically 
useful. Our data may suggest that anticollagen TFOs could be effective in future gene 
therapy for fibrosis in vital organs. 
 
 
4.2. Materials and Methods  
 
 
4.2.1. Materials 
 
TFO, which was a 25-mer antiparallel fully phosphorothioate ODN (3’-
GAGGGGGGAGGAGGGAAAGGAAGGG-5’) targeting rat α1(I) collagen gene 
promoter was synthesized by Invitrogen (Carlsbad, CA). Bovine serum albumin (BSA) 
(fraction V, purity>98%) was purchased from USB Corporation (Cleveland, OH). SYBR 
Green-1 dye universal master mix and MultiScribe reverse transcriptase were purchased 
from Applied Biosystems, Inc. (Foster City, CA). Tumor necrosis factor (TNF)-α ELISA 
kits were purchased from eBioscience, Inc. (San Diego, CA). RNA extraction kit was 
procured from Promega (Madison, WI). Immobilon polyvinylidene fluoride (PVDF) 
membrane was purchased from Millipore (Billerica, MA). Rabbit antirat TGF-β1 and β-
actin primary antibodies and horseradish peroxidase-conjugated goat antirabbit secondary 
antibody were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). 
Chemiluminescence (ECL) detection kit was purchased from GE Healthcare Life 
Sciences (Pittsburgh, PA). Serum alanine transaminase and aspartate transaminase kits 
were purchased from ID Labs, Inc (London, Canada). Citric acid and sodium citrate were 
procured from Curtin Matheson Scientific, Inc (Houston, TX). Sodium hydroxide was 
purchased from Fisher Scientific, (Fair Lawn, NJ). Hydroxyproline, Chloramine-T, 3, 3'-
diaminobenzidine (DAB) and goat serum were purchased from Sigma-Aldrich (St. Louis, 
MO). 
 
 
4.2.2. Animals and Experimental Design 
 
Male Sprague–Dawley rats weighing 250–280g were maintained under conditions as 
per the NIH (http://grants1.nih.gov/grants/olaw/references/phspol.htm) and institutional 
animal care and use Committee using the approved protocol. All animals were housed in 
microisolator cages in virus-free facilities and fed laboratory chow ad libitum. CBDL or 
sham operation was performed as described previously.192-194 After a midline laparotomy, 
liver lobes were retracted upwards and the intestines were reflected to the right to expose 
the common bile duct (CBD). The CBD was then isolated by careful blunt dissection, 
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doubly ligated with 4-0 silk and transected between the two ligations. The sham operation 
was performed similarly, with the exception of ligating and transecting the bile duct. 
Liver was then replaced into the abdominal cavity making sure there were no twists in the 
vascular pedicles of its lobes. The abdomen was closed with 4-0 silk running suture. Rats 
were injected with TFO at 8mg/kg per dose twice a week for 4 weeks via the tail vein. 
Sham operated rats and CBDL control rats were injected with an equal volume of saline. 
Animals were sacrificed after 7 weeks. Blood and liver tissue were collected for 
biochemical, RNA, histological and immunohistochemical studies. 
 
 
4.2.3. Cell Culture  
 
Immortalized rat hepatic stellate cells (HSC-T6) were a kind gift by Dr. Scott 
Friedman (Mount Sinai School of Medicine, New York). HSC-T6 cells at a density of 
1X106 cells were seeded on uncoated plastic tissue culture 6-well plates and cultured in 
Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL, Grand Island, NY) containing 
10% of fetal bovine serum (FBS) until 50% confluence was achieved. The growth 
medium was replaced with a pre-warmed serum-free DMEM. TFO was mixed with 
lipofectamine 2000 according to the manufacture’s protocol and then used for 
transfection. Scrambled TFO was used as control. 
 
 
4.2.4. Serum Transaminase Levels  
 
Serum levels of aspartate aminotransferase (AST) and alanine aminotransferase 
(ALT) were used as markers of liver injury. ALT and AST concentrations were measured 
using IDTox™ Alanine transaminase color endpoint assay kit and IDTox™ Aspartate 
transaminase enzyme assay kit (ID LabsTM Inc, London, ON, Canada) according to the 
manufacturer’s instructions and absorbance was measured using a spectrophotometer. 
 
 
4.2.5. Hydroxyproline Assay 
 
Hydroxyproline content was quantified colorimetrically from 30mg of liver tissue as 
previously described.195 Briefly, fresh liver tissue was collected and weighed at the time 
of sacrificing the animals. The tissue was then hydrolyzed with 6N HCl and then heated 
in an oven at 110°C for 18h. The tissue was incubated in a vacuum desiccator overnight 
until the HCl was completely dried. Citrate buffer was added to dilute the samples. Then, 
Chloramine-T reagent was added to the samples and allowed to react for 20 min at room 
temperature. Following this, fresh Ehrlich’s reagent was prepared and added to each 
sample. Samples were then placed in a warm water bath (60°C) and allowed to react for 
15 min. Samples were then cooled to room temperature and absorbance was read at 
550nm for each sample and a standard control. The results were expressed as micrograms 
of hydroxyproline per grams of liver. Hydroxyproline standard curve was also prepared 
using variable concentrations of it and plotting the standard curve after measuring the 
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absorbance at 560nm. Hydroxyproline levels correspond to the total amount of collagen 
present. 
 
 
4.2.6. ELISA for Tumor Necrosis Factor- 
 
Cell culture supernatant or serum was used to determine the levels of TNF- using an 
ELISA kit according to the manufacturer's specifications (eBiosciences, San Diego, CA). 
For in vitro studies, rat HSC-T6 cells were cultured as described above. Medium was 
removed and cells incubated in serum-free medium for 24h. Supernatants were collected 
and stored at-80°C until analysis. For in vivo studies, blood was collected immediately 
after euthanasia and centrifuged at 10,000 rpm for 7 min at room temperature to separate 
the serum. Serum was at-80°C for future use. ELISA data were then presented as the 
percentage (%) of the control for in vitro studies or picograms per milliliter of serum for 
in vivo studies. 
 
 
4.2.7. Myeloperoxidase (MPO) Activity Assay 
 
The presence of MPO, an enzyme specific for neutrophils, was used as an index of 
liver neutrophil accumulation. Briefly, the frozen tissue was thawed and placed in 4 ml 
iced 0.5% hexadecyltrimethylammonium bromide and 50 mmol potassium phosphate 
buffer solution with the pH adjusted to 5. Each sample was homogenized for 30 s and 
centrifuged at 15,000 rpm for 15 min at 4°C. Supernatants were then mixed with 
hydrogen peroxide–sodium acetate and tetramethyl benzidine solutions. The change in 
absorbance was measured spectrophotometrically at 460nm. One unit of MPO activity 
was defined as the quantity of enzyme degrading 1 mol peroxide per minute at 25°C per 
gram of tissue. 
 
 
4.2.8. Real Time Polymerase Chain Reaction  
 
To determine Type I collagen, alpha smooth muscle actin (α-SMA), TGF-β1, and 
tissue inhibitor of metalloproteinase 1 (TIMP-1) gene expression in rat liver, total liver 
RNA was extracted using RNeasy extraction kit (Qiagen, Valencia, CA). RNA 
concentration and purity was measured and confirmed using Nanodrop (Thermo 
Scientific, Wilmington, DE). Total RNA (385ng) was reverse transcribed to cDNA 
templates using MultiScribe reverse transcriptase and random hexamers by incubation at 
25°C for 10 min, followed by reverse transcription at 48°C for 30 min and enzyme 
inactivation at 95°C for 5 min. In all 100ng of cDNA was amplified by real time PCR 
using SYBR Green dye universal master mix on an LightCycler®480 (LC 480) (Applied 
Biosystems, Inc., Foster City, CA) using the primers (Table 4-1) for Type I collagen 
(NCBI Accession#NM_053304.1), α-SMA (NCBI Accession#NM_031004.2), TGF-
β1(NCBI Accession#NM_021578.2), TIMP-1(NCBI Accession#NM_053819.1). The 
PCR products were subjected to a melting curve analysis and crossing point (Cp) was 
used for calculating the relative amount of mRNA compared to the house keeping gene,  
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Table 4-1      Primers for real time PCR. 
 
Gene Forward Primer (5'-3') Reverse Primer (5'-3') 
α1(I) 
collagen TGGTCCCAAAGGTTCTCCTGGT TTAGGTCCAGGGAATCCCATCACA
α-SMA ACAACGTGCCTATCTATGAGGGCTAGCGACATAGCACAGCTTCTCCTT
TGF-β1 CATCCATGACATGAACCGACCCTTACAGAAGTTGGCATGGTAGCCCTT
TIMP-1 CCTCTGGCATCCTCTTGTTGCTAT CATTTCCCACAGCGTCGAATCCTT
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hypoxanthinephophoribosyltransferase (HPRT), and then scaled relative to controls, 
where control samples were set at a value of 1. Thus, results for all experimental samples 
were graphed as relative expression compared with the control. Melting curve analysis 
was also done to check the amplification specificity. 
 
 
4.2.9. Histological Staining 
 
Formalin-fixed liver specimens from the TFO treated, BDL and Sham operated rats 
were dehydrated in alcohols, incubated in xylene, and embedded in paraffin. Five-
micron-thick tissue sections were cut and stained with either hematoxylin-eosin for 
general histology or Masson’s trichrome for collagen staining, according to 
manufacturer's protocols. 
 
 
4.2.10. Immunofluorescent Staining 
 
Immunofluorescent staining was performed on snap frozen liver tissue. Briefly, 5m 
cryosections were cut on lysine coated slides and fixed in 95% cold ethanol. Slides were 
air dried and stored at -80ºC till further use. The sections were blocked with 10% goat 
serum with 1% BSA in PBS for 2h at room temperature. Cryosections then incubated 
with the following primary antibodies overnight at 4C: anti rabbit α- SMA, anti rabbit 
TGF-β, and anti-mouse cytoketain-19. The following secondary antibodies were used, 
anti-rabbit Alexa Fluor 488, anti-mouse Alexa Fluor 594 and anti-rabbit Alexa Fluor 594. 
Nuclear staining was performed using 4', 6-diamidino-2-phenylindole (DAPI). 
Immunofluorescence was visualized on a Zeiss Apoplan Microscopy system. 
 
 
4.2.11. Statistical Analysis 
 
Data are expressed as the mean±standard deviation (SD). Difference between any two 
groups was determined by ANOVA and t-test. P<0.05 was considered statistically 
significant. 
 
 
4.3. Results  
 
 
4.3.1. TFO Downregulates Type 1 (I) α-Collagen In Vitro  
 
HSCs were cultutred and transfected with 1µg of TFO. mRNA analysis showed a 
drastic decrease in the expression of type 1 (I) α-Collagen in the HSCs transfected with 
TFO inhibiting type 1 (I) α-Collagen compared to that of scrambled TFO and 
untransfected HSCs (Figure 4-1). 
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Figure 4-1 TFO down regulated type 1 (I) α-collagen in HSCs. 
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4.3.2. TFO Downregulates Profibrogenic and Proinflammatory Cytokines in HSCs In 
Vitro 
 
TGF-β1 and TIMP-1 are the two major profibrogenic cytokines implicated in the 
development of liver fibrosis.196-198 As shown in Figure 4-2A, transfection of HSC-T6 
cells with 1g of TFO complexed with Lipofectamine significantly attenuated expression 
of TIMP 1 and TGF-β1 mRNAs on real time PCR. Similarly, TFO significantly 
decreased proinflammatory cytokine TNF-α concentration in cultured medium as 
measured by ELISA (Figure 4-2B). 
 
 
4.3.3. TFO Attenuates Chronic Liver Injury in CBDL Rats 
 
To examine the effect of TFO on liver fibrosis, the common bile ducts of rats were 
ligated and at 3 weeks post CBDL, three rat livers were isolated to confirm liver fibrosis 
by evaluating i) macroscopically, ii) hydroxyproline assay and Masson’s trichrome 
staining (data not shown). Then, TFO was injected intravenously twice a week at a dose 
of 8mg/kg for 4 consecutive weeks and the degree of liver fibrosis was assessed by using 
three independent methods: collagen quantitation by measuring hydroxyproline content, 
Col 1A2 mRNA level in the liver samples and histological analysis by hematoxylin and 
eosin histological staining as well as Masson’s trichrome staining. Hydroxyproline is a 
quantitative measure of collagen deposition and fibrosis.199 As expected, there was 
significant increase in hydroxyproline content in the liver following CBDL, indicating 
that the liver fibrosis model was successfully established. TFO treatment reduced 
hydroxyproline content in the fibrotic liver, which was similar to that of the normal rats 
(Figure 4-3). 
 
To determine whether the decrease in hydroxyproline content in the liver of TFO 
treated CBDL rats was due to the transcription inhibition of α1(1) collagen, we 
determined collagen mRNA levels by real time PCR. The levels of α1(I) collagen mRNA 
(corrected by the steady-state levels of HPRT mRNA) were decreased in the liver of TFO 
treated CBDL rats.  
 
 
4.3.4. Histopathological Alterations 
 
Liver architecture of fibrotic livers with or without TFO treatment was determined by 
hematoxylin and eosin histological staining. As shown in Figure 4-4, there was 
significant number of bile infarcts noticed in the BDL liver sections. TFO treatment 
showed significant reduction in the bile infarcts. Figure 4-5 shows Masson’s trichrome 
staining of the liver sections of the control, CBDL and TFO-treated rat livers. In the 
control rats which were exposed to saline only, deposition of collagen was found 
surrounding the central veins and enclosing portal triads representing the collagen 
distribution of healthy livers. CBDL rats being treated with saline over 4 weeks displayed 
a periportal fibrosis characterized by portal-portal septa surrounding the lobules. Collagen 
deposition was extensive in the peribiliary and interstitial tissue. There were also  
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Figure 4-2 In vitro effect of TFO on HSC cells. 
 
A) Effect on TIMP1 and TGF-β1 expression after transfection of HSC-T6 cells with 
TFO after complex formation with lipofectamine 2000. At 72h post-transfection, cells 
were harvested, total RNA was extracted, and TIMP1 and TGF-β1 expression was 
determined at mRNA levels using real time PCR. B) TNF-β concentration in cultured 
medium was measured by enzyme-linked immunosorbent assay (ELISA). Data are 
expressed as the mean±standard deviation (SD).  
A B 
77 
 
 
 
Figure 4-3 Hydroxyproline assay. 
 
Total tissue hydroxyproline content was determined by biochemical assay at 7 weeks 
after BDL. Data are expressed as micrograms of hydroxyproline per milligram of tissue. 
Results are expressed as the mean±S.D. *P<0.05 compared with control using ANOVA 
and t-test. TFO treatment reduces hepatic hydroxyproline content. 
78 
 
 
 
Figure 4-4 Hematoxylin and Eosin staining of livers sections.  
 
TFO gene therapy attenuates liver fibrosis induced by BDL. Hematoxylin and Eosin 
staining staining of liver tissue sections from control, BDL and TFO–treated rats at 7 
weeks after BDL. 
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Figure 4-5 Masson’s Trichrome staining for collagen. 
 
TFO gene therapy attenuates liver fibrosis induced by BDL. Masson’s trichrome 
staining of liver tissue sections from control, BDL and TFO–treated rats at 7 weeks after 
BDL. Significantly less hepatic collagen staining was observed in TFO-treated rats. 
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confluent areas of necrotic hepatocytes in the collagenized zones. TFO administration, 
however, resulted in a marked reduction in the fibrotic stage indicated by decreasing 
portal and periportal accumulation of collagen and essentially no collagen accumulation 
was found in liver interstitium (Figure 4-5). Also, there was further reduction in 
branching of collagen in the liver sections of TFO treated rats compared to that of 
common bile duct ligated rats.  
 
A computer-aided morphometric analysis revealed that the intensity of collagen 
staining in the liver sections at 7 weeks after CBDL was reduced by 60% after TFO 
treatment, when compared with the saline treated CBDL rats. 
 
 
4.3.5. Effect of TFO on Liver Functions and Serum Fibrotic Markers 
 
ALT is a cytosolic enzyme, primarily present in the liver. An increase in plasma ALT 
indicates liver damage more specifically than AST, which is a mitochondrial enzyme 
present in large quantities in the heart, liver, skeletal muscle, and kidney and in part 
indicates liver injury. At 7 weeks post CBDL, serum AST and ALT levels as determined 
by colorimetric assay were significantly higher in BDL animals with no TFO treatment 
compared with the CBDL rats treated with TFO (Figure 4-6).  
 
 
4.3.6. TFO Attenuates In Vivo Myofibroblast Activation  
 
To provide further evidence of the anti-fibrotic properties of TFO in CBDL rats, we 
used real time RT-PCR to determine the effects of this compound on hepatic α-SMA 
protein expression, a well-established marker of HSC activation during liver 
fibrogenesis.200 Compared with sham controls, α-SMA mRNA expression in the CBDL 
liver at 7 weeks was markedly increased, suggesting activation of the hepatic 
myofibroblasts following CBDL-induced injury. However, the induction of α-SMA 
mRNA in the fibrotic liver was largely blocked by intravenous administration of TFO 
twice a week for four consecutive weeks at 3 weeks after CBDL (Figure 4-7). We next 
examined hepatic myofibroblast activation after CBDL by using immunofluorescence 
staining. In the normal rat liver, α-SMA was exclusively and strongly expressed in vessel 
walls (portal vessels and centrilobular veins). The staining for α-SMA was dramatically 
increased in CBDL liver forming whorls of layers (onion skinning) around the 
proliferated bile ductules. In addition to the peribiliary region in which α-SMA positive 
cells were observed, strong α-SMA staining was also found in enlarged and/or 
proliferated biliary epithelia (Figure 4-8). However, α-SMA staining was fairly week in 
the fibrotic liver after intravenous administration of TFO twice a week for four 
consecutive weeks at 3 weeks after CBDL (Figure 4-8). 
 
To confirm the epithelial origin of α-SMA-positive cells, we used double 
immunofluorescence staining for biliary epithelial marker cytokeratin-19 (red) and α-
SMA (green). Figures 4-9 and 4-10 demonstrate clear colocalization of cytokeratin-19 
and myofibroblast marker α-SMA in biliary epithelial cells at 7 weeks after CBDL. 
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Figure 4-6 Serum ALT and AST assay. 
 
Effect of TFO treatment on alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) content. ALT and AST levels were determined by colorimetric 
assay at 7 weeks after CBDL in rats TFO treatment reduces hepatic ALT and AST 
content compared to CBDL rats without any TFO treatment. Results are expressed as the 
mean±S.D. *P<0.05 compared with control using ANOVA. 
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Figure 4-7 Real time PCR analysis for α-SMA. 
 
Reverse transcription-PCR showed an inhibitory effect of TFO on α-collagen 
expression levels in BDL rats. The mRNA levels of α-collagen and α-SMA was 
determined by reverse transcription-PCR 7 weeks after BDL. *P<0.05 compared with 
control using ANOVA. 
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Figure 4-8 Immunoflorescent staining for α-SMA. 
  
Immunoflorescent staining for α-SMA in A) Control B) BDL and C) TFO treated 
liver sections at 10X magnification respectively. Arrows indicate the positive staining for 
α-SMA in and proliferated bile ductules. 
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Figure 4-9 Double immunostaining for cytokeratin-19 and α-SMA. 
 
Double immunostaining for cytokeratin-19 and α-SMA in A) Control B) BDL and C) 
TFO treated liver sections. The arrows indicate the colocalization of cytokeratin-19 and 
α-SMA indicating the phenomenon of epithelial-mesenchymal cell transition (EMT) 
occurring in and around the peribiliary space. 
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Figure 4-10 Colocalization of Cytokeratin-19 and α-SMA. 
 
Double immunostaining for cytokeratin-19 and α-SMA in A&B) BDL and C&D) 
TFO treated liver sections. Merging of cytokeratin-19 and α-SMA is shown in C&F. All 
the images are at 10X magnification.  
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Exogenous TFO, however, prevented the coexpression of cytokeratin-19 and α-SMA in 
biliary epithelium. These observations imply that biliary epithelial cells may undergo a 
phenotypic transition into myofibroblasts under pathological conditions and that 
exogenous TFO administration could protect the biliary epithelia by blocking this 
phenotypic transition. 
 
 
4.3.7. TFO Inhibits Neutrophil Infiltration by Downregulating Inflammatory 
Cytokines 
 
CBDL may cause hepatocyte apoptosis due to TNF-α upregulation and consequent 
neutrophil infiltration. Therefore, we determined the amount of TNF-α secreted from the 
livers of TFO treated and non-treated CBDL rats. There was only slight elevation in 
TNF-α level in the non-treated BDL group indicating only minor inflammation following 
the induction of liver fibrosis by bile duct ligation (Figure 4-11A). The level of 
myeloperoxidase (MPO) which is a marker for neutrophil infiltration was less in the TFO 
treated CBDL group compared to non-treated CBDL group, indicating that TFO 
treatment can decrease neutrophilic infiltration by inhibiting the release of inflammatory 
cytokine such as TNF-α (Figure 4-11B). 
 
 
4.4. Discussion 
 
Fibrosis is characterized by an excessive production of ECM components, especially 
Type I collagen, and if not controlled it can lead to organ dysfunction.201 Therefore, 
inhibition of collagen synthesis should prevent fibrosis. Joseph et al., demonstrated that 
antiparallel polypurine phosphorothioate oligonucleotides could form triplexes with the 
C1 region of the α1(I) collagen gene promoter and inhibit transcription of α1(I) collagen 
gene promoter activity in rat fibroblasts in culture.82 We determined triplex formation of  
a psoralen modified TFO with α1(I) collagen gene in isolated nuclei and intact HSC-T6 
cells, and demonstrated strong correlation between triplex formation and transcription 
inhibition of TFOs.191 HSCs are the key fibrogenic cells and upon activation they convert 
into myofibroblast- like cells, excrete excess ECM components, and overexpress TGF-β1 
and α-SMA, which are markers for myofibroblasts and fibronectin, respectively.202 
Therefore, in our previous studies, we isolated different liver cells after systemic 
administration of TFO and demonstrated almost 40% of the total liver recovery was in 
the HSCs.203 In the present study, we investigated the therapeutic effect of TFO on liver 
fibrosis in rats induced by CBDL, which is a commonly used animal model. 
 
The serum TNF-α levels were elevated following CBDL, and was noted to be lower 
in the TFO treated group (Figure 4-11A). TNF-α is an important mediator of 
hepatotoxicity and is upregulated in several animal models of chronic and acute liver 
injury. Gabele et al., have studied the effect of CBDL on TNF- α knockout mice and 
found them to be more resilient to the liver injury secondary to CBDL.204 They also 
showed that TNF-α knockout mice had a significant decrease in expression of collagen, 
α-SMA and TGF-β1 upon induction of fibrosis by BDL. Histopathological examination  
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Figure 4-11 TNF-α ELISA and Myeloperoxidase assay. 
 
A) Effect of in vivo TFO treatment on TNF-α. Rat serum was separated from the 
plasma. Following separation, TNF-α in serum were measured by enzyme-linked 
immunosorbent assay (ELISA). B) Myeloperoxidase (MPO) activity in the liver tissue of 
CBDL sham and TFO treated Time (Min) ELISA). CBDL, groups. One unit of MPO 
activity was defined as the amount of the MPO in 1 gram of liver tissue that could change 
1 OD in absorbance at 460nm. 
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of the liver tissue using Masson’s trichrome staining also revealed a decrease in staining 
after treatment with TFO twice a week for 4 consecutive weeks at 3 weeks post CBDL 
(Figure 4-5). In addition, the TFO treated group also showed less neutrophilic infiltration 
compared to the BDL group suggesting the attenuation of liver fibrosis. The increase in 
concentration of ALT and AST levels seen following BDL also showed a decreasing 
trend after TFO treatment indicating reduction of hepatic inflammation. Xia et al., have  
shown that mesenchymal cell transition (EMT) plays a vital role in the development of 
liver fibrosis due to CBDL.205 TGF-1 has also been shown to induce EMT transition to 
induce idiopathic pulmonary fibrosis.186 There have been reports, which suggest that the 
cultured neonatal rat hepatocytes undergo EMT at specific conditions.206 It will not be 
surprising if BECs undergo phenotypic transition to matrix–producing myofibroblasts 
after CBDL. It has also been seen that there is a decrease in the hepatic myofibroblast 
activation and biliary fibrosis when EMT was blocked by hepatocyte growth factor.205 
TGF-β1 is also an important factor resulting in EMT resulting in fibrosis. There are 
several reports in the literature which have showed that TGF-β1 can induce EMT 
upregulation of Smad-interacting protein-1 (SIP1) and Snail.206-208 In the present study, 
TGF-β1 levels were increased significantly following BDL as seen by Western blot. 
Treatment with TFO showed a significant reduction in TGF-β1 levels. (data not shown) 
These findings suggest that the transformed HSCs possibly secreted TGF-β1. This is also 
consistent with the current idea that HSCs are transformed into myofibroblasts and 
secrete TGF-β1, thus stimulating the production of ECM, and probably their 
proliferation, through a paracrine/autocrine loop. 
 
In the present study, we have shown that CBDL results in the transformation of 
biliary epithelial cells (BECs) to α-SMA expressing myofibroblasts which migrate into 
the periductal region through the impaired basement membrane. Most of BECs around 
the bile duct in CBDL rats were found positive for α-SMA (Figure 4-8) corroborating the 
fact that EMT may be the phenomenon behind the development of myofibroblasts. There 
was also considerable co-localization of both α-SMA and Cytokeratin-19 in the 
interstitium around the bile duct suggesting migration of newly formed myofibroblasts 
(Figures 4-9 and 4-10). 
 
TFO treatment can inhibit the transcription of Type I collagen and also decrease in α-
SMA levels in TFO treated group, suggesting that the inhibition of collagen can also lead 
to down regulation of α-SMA levels. This helps in attenuating fibrosis induced by CBDL. 
Furthermore, it also inhibits the EMT, thereby decreasing the development of 
profibrogenic cells and inhibiting the accumulation of ECM. This study shows that a TFO 
can have a beneficial effect on decreasing liver fibrosis and reversing progression of liver 
injury. Further studies would be required to understand the exact mechanism by which 
the TFO inhibits EMT. 
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CHAPTER 5. SUMMARY 
 
 
Transplantation therapy for diabetes is limited by the toxicity of immunosuppressive 
drugs. However, even if toxicity can be minimized, there will still be a shortage of human 
donor organs. Ex vivo transplantation of islets can be a viable alternative for treating 
diabetes. Transplantation of islets is a viable therapy for treating Diabetes. However, 
there are certain problems that need to be overcome. The major problems for islet 
transplantation are lack of revascularization following transplantation and the non-
function of islet grafts due to immune responses following transplantation. We used 
adenoviral vectors encoding VEGF/HGF and IL-1Ra genes which can help in 
revascularization of islets and protect the islets from immune mediated destruction.  
 
We constructed Adenoviral vector encoding VEGF and IL-1Ra. Initially we 
confirmed the expression of the genes, VEGF and IL-1Ra following transduction in 
human islets. There was very high expression of these genes from the Adv transduced 
islets compared to non-transduced islets. We further checked the functionality and 
viability of islets following Adv transduction. The stimulation indices of Adv transduced 
islets were similar to the non-transduced islets indication no detrimental effects from the 
Adv. Following this, we studied the effect of IL-1Ra in protecting the islets from 
apoptosis by incubating the Adv treated islets in a cytokine cocktail. The caspase-3 levels 
were less compared to that of the islets with no Adv transduction. We then transplanted 
islets transduced with the Adv-hVEGF-hIL-1Ra in the kidney capsules of NOD-SCID 
diabetic mice. The islets transduced with Adv showed better metabolic control and 
functionality and were able to lower the blood glucose levels for a long period of time 
compared to mice transplanted with non-transduced islets or control vector Adv- Lacz. 
There was also an increase in expression of insulin and c-peptide in mice transplanted 
with Adv compared to mice transplanted with non-transduced islets. 
Immunohistochemical staining of kidney sections revealed extensive staining for insulin 
and human vonWillebrand factor (marker for endothelial cells) in Adv-hVEGF-hIL-1Ra 
transduced islets. This shows that the bicistronic adenoviral vector indeed expressed the 
genes VEGF and IL-1Ra and was able to decrease the blood glucose levels in the 
Diabetic NOD-SCID mice.  
 
We then decided to replace VEGF with HGF as HGF can not only promote 
revascularization of islets, but also can further promote β- cell proliferation, function and 
survival following transplantation. HGF gene therapy also showed reduction in minimum 
islet transplant mass required for transplantation. Adenoviral-mediated gene transfer of 
HGF has been shown to improve islet transplant outcomes. HGF is also known to inhibit 
apoptosis. We constructed Adv-hHGF-hIL-1Ra and transduced them to human islets to 
see the expression of HGF and IL-1Ra. There was dose and time dependent expression of 
both the genes from the vector. The Adv vectors were relatively safe at lower dose of 
around 1000 MOI with the stimulation index being similar to that of control non-
transduced islets. Then we studied the effect of Adv in protecting the islets from 
apoptosis. The islets transduced with Adv-hHGF-hIL-1Ra showed less expression of 
caspase-3 compared to control indicating the effectiveness of Adv in protection from 
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apoptosis. Transplantation of islets transduced with Adv-hHGF-hIL-1Ra showed better 
metabolic function and decreased the blood glucose levels for a longer time compared to 
NOD-SCID mice transplanted with non-transduced islets. Immunohistochemical staining 
of kidney sections showed extensive staining for insulin and hVw factor for Adv 
transplanted islets compared to that of non-transplanted control. At the end of in vivo 
study, intraperitoneal glucose tolerance test (IPGTT) was done to study the metabolic 
function of transplanted islets. The mice transplanted with Adv transduced islets behave 
well compared to those with non-transduced islets. 
  
In summary bipartite Adenoviral vectors which are replication–deficient can be used 
successfully for transducing islets for improving the islet transplantation outcomes. We 
saw a decrease in blood glucose levels in NOD-SCID mice transplanted with Adv 
transduced islets and further these islets were able to decrease the blood glucose levels 
for a sustained period of time. Adv vectors were relatively safe at MOI up to 1000 and 
showed efficient expression of VEGF, HGF and IL-1Ra corroborating the literature. 
More studies reflecting the immune responses from these vectors need to be studied to 
further confirm the beneficial effects of these vectors in islet transplantation. Further, 
HGF thereapy can decrease the number of islets needed for transplantation, which is very 
crirtical as there is an enormous shortage in islets required to attain euglycemia. 
 
Liver fibrosis is a result of accumulation of fibrous, scar tissue in the liver. It usually 
occurs due to the injury to liver cells (hepatocytes) by trauma, viral infection, excessive 
alcohol consumption, toxins or other factors that lead to increase in activation of immune 
system and resulting in the excessive accumulation of ECM. The hepatic stellate cells 
(HSCs) get activated resulting in inflammation of hepatocytes causing excessive 
accumulation of Type I collagen and ECM. It is often associated with high morbidity and 
mortality and can lead to the need for a liver transplant. There has been no proper therapy 
for liver fibrosis till now. Bile duct ligation is the most frequently used method in 
developing fibrosis. We have evaluated the use of TFOs inhibiting Type I collagen in 
attenuating fibrosis induced by bile duct ligation. BDL is a commonly used animal model 
for inducing fibrosis in liver. Biliary fibrosis can be caused either due to biliary atresia or 
primary sclerosing cholangitis. The injury to the bile duct by performing BDL may 
trigger a chain of events resulting in the development of fibrosis.  
 
We have shown that BDL results in the transformation of BECs to α-SMA expressing 
myofibroblasts which apparently migrate into the periductal region through the impaired 
basement membrane. Most of the BECs around the bile duct in BDL rats were found 
positive for α-SMA corroborating the fact that EMT may be the phenomenon behind the 
development of myofibroblasts. Further, colocalization of α-SMA and Cytokeratin-19 in 
the BECs confirmed the phenotypic transition of BECs to mesenchymal cells.  There was 
considerable colocalization of both α-SMA and Cytokeratin-19 in the interstitium around 
the bile duct signifying the migration of newly formed myofibroblasts. This phenomenon 
was mitigated in the animals treated with TFO inhibiting Type I collagen.  TGF-β1 can 
be an important factor resulting in biliary EMT of hepatocytes resulting in fibrosis. TGF-
β1 levels were increased significantly following BDL as seen by western blot and Real 
time PCR analysis. Treatment with TFO showed a significant reduction in the TGF-β1 
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levels. There was also a decrease in the α-SMA levels in the TFO treated group compared 
to the non-treated BDL group suggesting that the inhibition of collagen can also lead to 
down regulation of α-SMA levels. 
 
The hydroxyproline levels in TFO treated group was very less compared to the BDL 
group. This is in line with our previous studies suggesting the inhibition of transcription 
of Type I collagen. The serum TNF-α levels were elevated following BDL, and was 
higher than that in the TFO treated group. TNF-α is a mediator of hepatotoxicity and is 
upregulated in several animal models of chronic and acute liver injury. Masson’s 
trichrome staining revealed a significantly high staining for collagen in liver sections 
obtained from BDL group which decreased after treatment with TFO. There was also 
seen an increase in concentrations of ALT and AST levels following BDL. TFO 
treatment showed a decrease in the concentrations of the ALT and AST levels indicating 
the effectiveness of TFO in attenuating liver fibrosis. 
 
TFO treatment inhibiting the transcription of Type I collagen helps in attenuating 
fibrosis induced by BDL. It also further inhibits the EMT, thereby decreasing the 
development of profibrogenic cells and inhibiting the accumulation of ECM. Although, 
the mechanism of TFO inhibiting the EMT needs to be thoroughly investigated, this 
study shows the beneficial effects of TFO and it can be a good candidate for treating 
fibrotic disorders. 
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